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The development of guidelines recommendations is one of the core activities of the European Society for Medical Oncology
(ESMO) and European Society of Gynaecologial Oncology (ESGO), as part of the mission of both societies to improve the quality
of care for patients with cancer across Europe. ESMO and ESGO jointly developed clinically relevant and evidence-based
recommendations in several selected areas in order to improve the quality of care for women with ovarian cancer. The ESMO–
ESGO consensus conference on ovarian cancer was held on 12–14 April 2018 in Milan, Italy, and comprised a multidisciplinary
panel of 40 leading experts in the management of ovarian cancer. Before the conference, the expert panel worked on five
clinically relevant questions regarding ovarian cancer relating to each of the following four areas: pathology and molecular
biology, early-stage and borderline tumours, advanced stage disease and recurrent disease. Relevant scientific literature, as
identified using a systematic search, was reviewed in advance. During the consensus conference, the panel developed
recommendations for each specific question and a consensus was reached. The recommendations presented here are thus
based on the best available evidence and expert agreement. This article presents the recommendations of this ESMO–ESGO
consensus conference, together with a summary of evidence supporting each recommendation.
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Introduction
The development of guidelines recommendations is one of the
core activities of both the European Society for Medical Oncology
(ESMO) and the European Society of Gynaecologial Oncology
(ESGO), as part of their mission to improve the quality of care for
patients with cancer across Europe. The objectives of these recom-
mendations are to improve and to harmonise the management of
patients with ovarian cancer. ESMO and ESGO decided to jointly
hold a consensus conference aiming at updating current know-
ledge relevant to the management of ovarian cancer.
Ovarian cancer is the leading cause of death among all gynaeco-
logical cancers in developed countries, with most patients present-
ing with advanced stage tumours, as defined by the spread of the
disease outside the pelvis [International Federation of Obstetrics
and Gynaecology (FIGO) stage III and IV]. The estimated number
of new ovarian cancer cases in Europe in 2012 was 65 538 with
42 704 deaths [1]. More than two-thirds of patients are diagnosed
at an advanced stage. More than 90% of malignant ovarian tumours
are of epithelial origin, designated epithelial ovarian cancer (EOC).
The most common and most lethal EOC is high-grade serous car-
cinoma (HGSC). Recent evidence suggests that most ‘extrauterine’
HGSCs arise from the fallopian tube and recommendations are pre-
sented for designating the site of origin of these neoplasms based on
our current knowledge of the site of origin and precursor lesions.
Responsibilities
These recommendations are a statement of evidence and consen-
sus of the authors regarding their views of currently accepted
approaches to diagnosis and treatment. They do not include any
economic analysis of the strategies. Any clinician applying or con-
sulting these recommendations is expected to use independent
medical judgment in the context of individual clinical circumstan-
ces to determine any patient’s care or treatment. These recommen-
dations make no representations nor warranties of any kind
regarding their content, use or application and the authors dis-
claim any responsibility for their application or use in any way.
Methods
Two consensus conference chairs (N. Colombo, D. Querleu)
were appointed. The consensus panel comprised 40 experts in the
management of ovarian cancer and included representation from
ESMO and ESGO (see Appendix). Each panel member was
assigned to one of four working groups (WGs), with a WG chair
and co-chair appointed for each group. Each WG was assigned a
subject area as follows:
1. Pathology and molecular biology (Chair: W.G. McCluggage;
Co-Chair: I. McNeish)
2. Early-stage and borderline tumours (Chair: P. Morice; Co-
Chair: I. Ray-Coquard)
3. Advanced stage disease (Chair: S. Pignata; Co-Chair: I.
Vergote)
4. Recurrent disease (Chair: A. du Bois; Co-Chair: J. Ledermann)
The methodology and medical writing support was provided by
F. Planchamp and each WG was assisted by a fellow (T. Baert, I.
Belaroussi, A. Dashora, S. Olbrecht). These five individuals did
not participate in the voting of consensus recommendations.
The consensus conference was held on 12–14 April 2018 in
Milan, Italy. Before this consensus conference, the WG chairs
were asked to identify five clinically relevant questions for each
subject area/WG, giving a total of 20 clinically relevant questions.
To ensure that the recommendations were evidence-based, the
literature was reviewed. A systematic literature review of the stud-
ies published between January 2007 and December 2017 was car-
ried out using the Medline database (see Section 1 of
supplementary data, available at Annals of Oncology online). The
literature search was limited to publications in English. Priority
was given to high-quality systematic reviews, meta-analyses and
randomised controlled trials (RCTs), but lower levels of evidence
were also evaluated. The reference list of each identified
article was reviewed for other potentially relevant papers. Each
WG was responsible for reviewing the relevant literature in order
to draft preliminary recommendations relating to each of their
assigned questions.
During the conference, in parallel sessions, the four WGs dis-
cussed and reached agreement on recommendations relating to
each of their assigned questions. Recommendations from each
group were then presented to the entire panel of experts, where
they were discussed and modified as required. An adapted ver-
sion of the ‘Infectious Diseases Society of America-United States
Public Health Service Grading System’ [2] was used (see Table 1)
to define the level of evidence (LoE) and grade of recommenda-
tion (GoR) for each of the recommendations proposed by the
group. Finally, members were asked to vote on each recommen-
dation; members were allowed to abstain from voting in cases
where they either had insufficient expertise to agree/disagree with
the recommendation or if they had a conflict of interest that
could be considered as influencing their vote. The recommenda-
tions from this consensus conference, together with a summary
of evidence supporting each recommendation, are detailed in this
article. A summary of all recommendations is included in supple-
mentary Table S1, available at Annals of Oncology online.
Results
Pathology and molecular biology
1. How to determine the site of origin of extrauterine HGSCs?
Despite growing evidence in support of the fallopian tube origin
of a significant majority of extrauterine HGSCs [3–5], there con-
tinues to be disagreement on primary site assignment. This has
implications for cancer registration and epidemiological analyses,
and results in differences in the staging of low-stage disease [6].
Continuing doubt on origin perpetuates the belief that there is a
true biological entity of ‘primary peritoneal HGSC’, currently
defined in the 2014 World Health Organization (WHO) classifi-
cation [7] as a disease of exclusion, to be designated only in cases
with no gross or microscopic evidence of mucosal disease in ei-
ther the tubes or the ovaries. Most significantly, continuing scep-
ticism regarding the tubal origin is an obstacle to studying the
impact of ovary-conserving preventative strategies that have po-
tential to reduce HGSC incidence and mortality.
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Studies on the origin of sporadic HGSC in the past have
been hampered by its presentation with disseminated disease,
technical challenges in performing molecular studies on
formalin-fixed paraffin-embedded tissues and incomplete tubal
examination; complete tubal sampling using detailed
Sectioning and Extensively Examining the FIMbriated End
(SEE-FIM) protocols is an essential prerequisite for identifying
and sampling the microscopic precursor lesion of HGSC, serous
tubal intraepithelial carcinoma (STIC). While STIC is reported
to be present in 11%–61% of HGSC cases, reports on low-stage
and optimally examined cases clearly demonstrate that virtually
all contain STIC or small microscopic tubal HGSC [8–11].
These studies also show that examples of single-site disease are
always tubal and never ovarian. Furthermore, while ovarian in-
volvement in HGSC is typically bilateral, as is common in me-
tastasis to a paired organ, tubal involvement is unilateral in the
majority of cases [12]. These observations are supported by
detailed molecular analysis demonstrating shared TP53 muta-
tion between STIC and HGSC, and that the majority of muta-
tional and copy abnormalities seen in HGSC are also identified
in accompanying STIC [13]. Clonal evolution studies demon-
strate the same result [14, 15] but also show that, in advanced
cases, intraepithelial tubal metastasis can produce lesions indis-
tinguishable from STIC, further demonstrating the futility of
studying advanced HGSC to answer questions about its origin.
What these and other studies have demonstrated irrefutably is
that, despite being widely disseminated at presentation in the
majority of cases, HGSC arises from a single precursor clone,
and there is no molecular evidence of multifocal origin [16, 17].
A proposal for primary site assignment in extrauterine HGSC is
recommended for reproducible categorisation (see Table 2),
with its basis in scientific evidence in favour of traditional
beliefs [7, 18]; this has been recommended for use in inter-
national ovarian cancer pathology reporting guidelines [19].
This evidence also forms the basis for recommendations on uni-
form staging of low-stage HGSC in cases that are left to the
pathologist’s and clinician’s discretion in the current FIGO
system [20, 21], resulting in potential for identical cases to be
staged differently [6]. It should be emphasised that these criteria
are only to be used for HGSC and not for other histological
types of EOC.
Recommendation 1.1: a large majority of extrauterine HGSCs
arise in the fallopian tube from STIC. SEE-FIM sectioning of
both fallopian tubes should be carried out in all cases of extra-
uterine HGSC where the tubes are grossly normal, and also in
risk-reducing prophylactic surgery specimens.
Level of evidence: III
Strength of recommendation: A
Consensus: 100% (40) yes, 0% (0) no, 0% (0) abstain (40 voters)
Recommendation 1.2: extrauterine HGSC can only be assigned
as ovarian in origin if both fallopian tubes are grossly normal,
and histologically contain no mucosal disease following examin-
ation using a SEE-FIM protocol.
Level of evidence: III
Strength of recommendation: A
Consensus: 100% (40) yes, 0% (0) no, 0% (0) abstain (40 voters)
Recommendation 1.3: cases in which HGSC is present in the
endometrium and the tube/ovary are very likely to represent a
primary at one site with metastasis to the other; these are very un-
likely to represent synchronous independent neoplasms.
Level of evidence: V
Strength of recommendation: A
Consensus: 97.5% (39) yes, 2.5% (1) no, 0% (0) abstain (40 voters)
Recommendation 1.4: the distinction between primary endo-
metrial and primary tubal/ovarian HGSC requires assessment of
a constellation of pathological features; negative wild-type 1
(WT1) staining favours an endometrial primary, but this is not
always definitive.
Level of evidence: V
Strength of recommendation: A
Consensus: 92.5% (37) yes, 0% (0) no, 7.5% (3) abstain (40 voters)
Table 1. Levels of evidence and grades of recommendation (adapted from the Infectious Diseases Society of America-United States Public Health Service
Grading Systema)
Levels of evidence
I Evidence from at least one large randomised, controlled trial of good methodological quality (low potential for bias) or meta-analyses of well-
conducted randomised trials without heterogeneity
II Small randomised trials or large randomised trials with a suspicion of bias (lower methodological quality) or meta-analyses of such trials or of trials
with demonstrated heterogeneity
III Prospective cohort studies
IV Retrospective cohort studies or case–control studies
V Studies without control group, case reports, expert opinions
Grades of recommendation
A Strong evidence for efficacy with a substantial clinical benefit, strongly recommended
B Strong or moderate evidence for efficacy but with a limited clinical benefit, generally recommended
C Insufficient evidence for efficacy or benefit does not outweigh the risk or the disadvantages (adverse events, costs, etc.), optional
D Moderate evidence against efficacy or for adverse outcome, generally not recommended
E Strong evidence against efficacy or for adverse outcome, never recommended
aBy permission of the Infectious Diseases Society of America [2].
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Recommendation 1.5: the use of uniform criteria is important
in site assignment in extrauterine HGSC for cancer registry and
epidemiological reasons. The use of International Collaboration
on Cancer Reporting (ICCR) and College of American
Pathologists (CAP) guidelines is recommended.
Level of evidence: V
Strength of recommendation: A
Consensus: 100% (40) yes, 0% (0) no, 0% (0) abstain (40 voters)
Recommendation 1.6: correct and uniform use of site assign-
ment criteria is particularly important for accurate staging of
early HGSC.
Level of evidence: III
Strength of recommendation: A
Consensus: 100% (40) yes, 0% (0) no, 0% (0) abstain (40 voters)
Recommendation 1.7: STIC should count as a disease site for
staging purposes; for example, a case with a STIC and HGSC con-
fined to the ovary should be staged as stage IIA fallopian tube
HGSC.
Level of evidence: IV
Strength of recommendation: A
Consensus: 95% (38) yes, 0% (0) no, 5% (2) abstain (40 voters)
Recommendation 1.8: true primary peritoneal HGSC is ex-
tremely rare.
Level of evidence: IV
Strength of recommendation: A
Consensus: 100% (40) yes, 0% (0) no, 0% (0) abstain (40 voters)
Recommendation 1.9: multifocal origin of extrauterine HGSC
is exceptionally rare and thus HGSC currently staged as IB should
be considered as stage IIA.
Level of evidence: IV
Strength of recommendation: A
Consensus: 95% (38) yes, 5% (2) no, 0% (0) abstain (40 voters)
2. How to identify tumours that will respond to targeted
therapies, including poly(adenosine diphosphate-ribose) polymer-
ase inhibitors and immune checkpoint inhibitors?
The targeted therapies that are under investigation include antian-
giogenic agents, poly(adenosine diphosphate-ribose) polymerase
(PARP) inhibitors, hormone receptor modulators and immune
checkpoint inhibitors. Bevacizumab, an antivascular epithelial
growth factor (anti-VEGF) monoclonal antibody has shown posi-
tive results in first-line therapy with standard chemotherapy and
also in both platinum-sensitive and platinum-resistant relapsed
disease, with improved progression-free survival (PFS) in various
large RCTs [22–25]. Improvements in overall survival (OS) have
been harder to demonstrate and are currently limited to a retro-
spective analysis of high-risk patients within the ICON7 trial [22].
Although therapy targeting VEGF has become the standard of care
in tubo-ovarian carcinomas as well as other solid malignancies,
attempts to identify predictive molecular biomarkers for efficacy
have failed to identify any that could help oncologists decide who
should and, more importantly, who should not receive VEGF-
targeted therapies, including bevacizumab [26].
Angiogenic markers, such as CD31 expression, microvessel
density and tumour VEGF-A levels, may provide prognostic in-
formation in recurrent/persistent EOC, and were identified in a
retrospective analysis of the Gynecologic Oncology Group
(GOG) 218 study as potential predictive biomarkers [27], but
further prospective evaluation will be required. Another study
showed a discriminatory signature comprising mesothelin, FLT4,
alpha-1 acid glycoprotein (AGP) and cancer antigen 125 (CA-
125) as potentially identifying those patients with EOC more like-
ly to benefit from bevacizumab [28]. A potential role of com-
bined values of Ang1 and Tie2 as predictive biomarkers for
improved PFS in bevacizumab-treated patients with EOC has
also been suggested. However, these findings need to be validated
in larger trials [29]. Currently, only clinical biomarkers (includ-
ing stage, debulking status and presence of ascites) appear to have
Table 2. Criteria for assignment of primary site in extrauterine HGSC
Criteria Primary site Comment
STIC present Fallopian tube Regardless of presence and size of ovarian and peritoneal disease
Invasive mucosal carcinoma in tube, with or with-
out STIC
Fallopian tube Regardless of presence and size of ovarian and peritoneal disease
Fallopian tube partially or entirely incorporated
into tubo-ovarian mass
Fallopian tube Regardless of presence and size of ovarian and peritoneal disease
No STIC or invasive mucosal carcinoma in either
tube in presence of ovarian mass or microscopic
ovarian involvement
Ovary Both tubes should be clearly visible and fully examined by a standar-
dised SEE-FIM protocol
Regardless of presence and size of peritoneal disease
Both tubes and both ovaries grossly and micro-
scopically normal (when examined entirely) or
involved by benign process in the presence of
peritoneal HGSC
Primary peritoneal HGSC As recommended in the 2014 WHO classification [7], this diagnosis
should only be made in specimens removed at primary surgery be-
fore any chemotherapy; see below for samples following
chemotherapy
HGSC diagnosed on small sample, peritoneal/
omental biopsy or cytology, OR HGSC examined
post-chemotherapy
Tubo-ovarian Note: this should be supported by clinicopathological findings to ex-
clude mimics, principally uterine serous carcinoma
HGSC, high-grade serous carcinoma; SEE-FIM, Sectioning and Extensively Examining the FIMbriated End; STIC, serous tubal intraepithelial carcinoma; WHO,
World Health Organization.
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predictive utility in selecting patients for first-line treatment with
bevacizumab and thus, prospective studies evaluating predictive
biomarkers of bevacizumab benefit are urgently required.
At the time of diagnosis, 50% of EOCs may exhibit defective
DNA repair via homologous recombination (HR) due to genetic
and epigenetic alterations of HR pathway genes [30]. Defective
HR is an important therapeutic target in EOC as exemplified by
the efficacy of platinum analogues in this disease, as well as the
advent of PARP inhibitors that exhibit synthetic lethality when
applied to HR-deficient cells. PARP inhibitors, such as olaparib,
niraparib and rucaparib, are being utilised in the clinic to manage
recurrent EOCs that display defects in the HR repair pathway.
However, PARP inhibitors also show significant clinical benefit
in patients without demonstrable defects in known HR genes.
Various studies validated this and extended the usefulness of
PARP inhibitors in the treatment setting beyond BRCA-mutated
tumours [31, 32].
The strongest clinical evidence for the use of PARP inhibitors
comes from patients with germline or somatic mutations in
BRCA1 or BRCA2, both as single-agent therapy and as mainten-
ance following response to platinum chemotherapy in the first-
line [33] and relapsed [34–36] settings. Rucaparib also has robust
activity as single-agent therapy in relapsed BRCA-mutated HGSC
[32], and the ARIEL2 study [32] demonstrated that tumours har-
bouring mutations in RAD51C alterations are BRCA-like [high
genomic loss of heterozygosity (LOH)] and responded to ruca-
parib at very similar rates to BRCA-mutated disease. However,
attempts to identify robust predictive biomarkers of response to
PARP inhibitors in HGSC beyond key HR gene mutations have
proven difficult. The ARIEL2 study [32] utilised genome-wide
LOH as a potential predictive biomarker, and showed that BRCA
WT/LOH high tumours did indeed have higher response rates
and improve PFS compared with BRCA WT/LOH low, but lower
than BRCA-mutated. However, attempts to use LOH as a predict-
ive marker in the maintenance setting were less successful. The
ARIEL3 study [37] evaluated rucaparib versus placebo as main-
tenance treatment in patients with recurrent platinum-sensitive
cancer and found rucaparib maintenance treatment significantly
improved PFS versus placebo in the nested BRCA-mutated and
HR deficiency (HRD) cohorts and in the overall intention-to-
treat (ITT) population. PFS was improved with rucaparib main-
tenance treatment versus placebo in patients with BRCA WT
EOC (LOH high and LOH low) as well. The NOVA study [38]
utilised a different algorithm to identify potential HRD tumours
and again found that, in patients who had responded to platinum
in the relapse setting, the median PFS was significantly longer
among those receiving niraparib than among those receiving pla-
cebo, regardless of the presence or the absence of germline BRCA
mutations or HRD status. Thus, in the maintenance setting, re-
sponse to platinum chemotherapy remains the most robust pre-
dictive biomarker for PARP inhibitor benefit.
A major limitation of the current HR assays is that they are
largely insensitive to reversion of HRD, which may occur upon
development of resistance to platinum and PARP inhibitors.
True functional assays of HR function exist, but they require the
cancer specimen to be exposed to some form of DNA damage,
which precludes use of formalin-fixed, paraffin-embedded speci-
mens, increases the technical complexity and limits the reprodu-
cibility of these assays. Overall, there is currently no prospectively
validated biomarker of HRD that has been incorporated
into clinical practice, and this remains an active area of investiga-
tion [39].
Bowman et al. [40] demonstrated that higher levels of
oestrogen receptor (ER) expression in EOC resulted in disease
stabilisation and CA-125 response after treatment with the
aromatase inhibitor letrozole, and suggested the presence of
an endocrine-sensitive group that could be targeted in future
studies. Similar results were later published by other groups,
suggesting that ER/progesterone receptor (PR) expression sta-
tus may be a predictive biomarker for hormonal therapy [41,
42]. There are no positive prospective randomised data for
the use of hormone therapies as alternatives to chemotherapy
or as maintenance therapy in first-line or recurrent disease,
even in low-grade serous carcinoma (LGSC). RCTs incorpo-
rating hormone therapy are required, especially in LGSC.
Prospective validation of ER score as a predictive biomarker
is also required, as there is no validated or universally used
ER score in EOCs.
Recommendation 2.1: there are no validated predictive mo-
lecular biomarkers of bevacizumab benefit.
Level of evidence: IV
Strength of recommendation: A
Consensus: 100% (40) yes, 0% (0) no, 0% (0) abstain (40 voters)
Recommendation 2.2: PARP inhibitors have greatest activity
in patients with BRCA1/2 mutations.
Level of evidence: I
Strength of recommendation: A
Consensus: 100% (40) yes, 0% (0) no, 0% (0) abstain (40 voters)
Recommendation 2.3: testing for BRCA1/2 mutations is rec-
ommended for all patients with non-mucinous ovarian cancer.
Level of evidence: I
Strength of recommendation: A
Consensus: 95% (38) yes, 0% (0) no, 5% (2) abstain (40 voters)
Recommendation 2.4: testing for mutations in other HR genes,
in particular RAD51C/D, BRIP1 and PALB2, should be
considered.
Level of evidence: III
Strength of recommendation: A
Consensus: 100% (40) yes, 0% (0) no, 0% (0) abstain (40 voters)
Recommendation 2.5: current assays of HR function cannot be
used to exclude patients from PARP inhibitor therapy.
Level of evidence: I
Strength of recommendation: A
Consensus: 100% (40) yes, 0% (0) no, 0% (0) abstain (40 voters)
Recommendation 2.6: moderate-strong ER staining may be a
predictor of response to hormone therapy.
Level of evidence: III
Strength of recommendation: B
Consensus: 100% (40) yes, 0% (0) no, 0% (0) abstain (40 voters)
Recommendation 2.7: there are currently no prospectively
validated predictive biomarkers of response to immune check-
point inhibitors that are specific to ovarian cancer.
Level of evidence: V
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Strength of recommendation: A
Consensus: 100% (40) yes, 0% (0) no, 0% (0) abstain (40 voters)
3. How to identify patients with acquired/intrinsic resistance to
chemotherapy?
Although most patients with HGSC initially respond to
platinum-based chemotherapy, the large majority of patients will
relapse. Thus, resistance to platinum-based treatment is com-
mon, with roughly 20% of women experiencing disease progres-
sion 6 months after completing a platinum-based regimen
(previously classified as ‘platinum-resistant’ relapse) or who fail
to respond at all to first-line treatment or relapse within 4–
6 weeks after last platinum dose (previously classified as ‘plat-
inum-refractory’) [43]. There have been many efforts over the
years to develop accurate predictors of outcomes in patients
treated with chemotherapy to help inform treatment decisions
[44].
Elucidation of why platinum resistance occurs and how it can
be reversed or prevented is essential for improving survival.
However, the WG unanimously agreed that there are no validated
predictive biomarkers that can be used in clinical practice for
determining likelihood of primary platinum-refractory or
platinum-resistant disease.
It is widely accepted that most HGSCs (60%–80%) show a
good response to conventional platinum-based chemotherapy.
However, low-grade serous, mucinous, clear cell and endome-
trioid ovarian carcinomas are considered to be less chemorespon-
sive and to have a different prognosis, although in many cases
they present at an early stage, in contrast to HGSCs, which usually
present at advanced stage. The large majority of patients enrolled
in clinical trials have HGSC histology and thus the results from
these studies cannot automatically be applied to all histological
types, where numbers recruited to all-comer studies are low and
where there are generally very few specific studies [45].
With better understanding of the molecular biology of EOCs,
DNA damage repair through HR is known to play a vital role in
contributing to genomic stability and preventing malignant
transformation. Numerous studies have reported that mutation
in BRCA1 or BRCA2 is a prognostic marker in EOC and con-
cluded that patients with BRCA mutation, especially BRCA2,
have better survival outcomes, which is likely to reflect increased
response rates to platinum-based chemotherapy [46–48].
Germline or somatic mutations in HR genes are present in up
to one-third of EOCs, including both serous and non-serous his-
tologies. In addition, Pennington et al. [49] looked at somatic
and germline mutations in 13 HR genes (BRCA1, BRCA2, ATM,
BARD1, BRIP1, CHEK1, CHEK2, FAM175A, MRE11A, NBN,
PALB2, RAD51C, RAD51D). They concluded that somatic muta-
tions in other HR genes have a similar positive impact on OS and
platinum responsiveness as germline BRCA1/2 mutations. HR
mutations were more successful in predicting platinum sensitiv-
ity at primary treatment than at relapse [49]. Other potentially
important mutations include CDK12, loss of which may induce
an HRD phenotype [50], although this needs further validation,
as not all alterations will have the same effect on HR repair and
sensitivity to platinum. Whole-genome studies in HGSC reveal
that gene breakage commonly inactivates the tumour suppressors
RB1, NF1, RAD51B and PTEN and contributes to acquired
chemotherapy resistance. CCNE1 amplification is common in
primary resistant and refractory disease, demonstrating the role
of non-HRD molecular mechanisms in resistance development
[51, 52]. An association between excision repair cross-
complementation group 1 (ERCC1) polymorphism and plat-
inum sensitivity has been reported in a few studies but with con-
flicting results; hence, this is not suitable for assessing platinum
response [53–55].
Finally, in patients with relapsed disease, the current classifica-
tion strictly defines platinum resistance as those relapsing within
6 months of previous platinum chemotherapy. However, because
time since last platinum chemotherapy represents a continuum
of probability of response to further chemotherapy, a fixed 6-
month cut-off decision on platinum sensitivity is neither sensible
nor biologically relevant. In addition, the effect of maintenance
therapies on the probability of response to further platinum is
unknown. The time since last platinum chemotherapy correlates
with response to other agents including PARP inhibitors, al-
though this is not absolute [56]. Large-scale trials collecting serial
biological samples throughout treatment are required in order to
improve the understanding of acquired resistance. In addition,
investigation and validation of markers should be carried out
using samples taken immediately before and during the therapy
of interest rather than using archival samples.
Recommendation 3.1: there are no validated predictive
markers of primary platinum refractory or resistant disease.
Level of evidence: IV
Strength of recommendation: A
Consensus: 100% (40) yes, 0% (0) no, 0% (0) abstain (40 voters)
Recommendation 3.2: defects in HR repair are associated with
improved outcome/PFS following platinum-based
chemotherapy.
Level of evidence: IV
Strength of recommendation: A
Consensus: 100% (40) yes, 0% (0) no, 0% (0) abstain (40 voters)
Recommendation 3.3: the time elapsed since last platinum
chemotherapy represents a continuum of probability of response
to further chemotherapy.
Level of evidence: IV
Strength of recommendation: A
Consensus: 100% (40) yes, 0% (0) no, 0% (0) abstain (40 voters)
4. Can we develop accurate and sensitive circulating and tissue
biomarkers both of response and relapse?
The Gynecologic Cancer InterGroup (GCIG) has published a
consensus document regarding the criteria that should be used in
clinical trial protocols to define PFS after first-line therapy, as
well as the criteria to define response to treatment in recurrent
disease using the serum marker CA-125, and has specified the sit-
uations where these criteria should be used [57]. This WG agrees
to the utility of these criteria in routine practice but emphasises
the importance of correlation with radiological and clinical
assessment.
CA-125 levels have been most widely studied in HGSC. The
prognostic value of CA-125 in other morphological types of
EOC, such as low-grade serous, clear cell, endometrioid and mu-
cinous, is less clear due to the relative rarity of these neoplasms in
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the advanced disease setting and the limited number of patients
studied in trials. As a result, CA-125 is not a reliable marker in
non-HGSC EOC [58, 59], in particular in mucinous carcinoma,
where it is rarely secreted. Caution is also recommended when
using CA-125 as a response marker for molecularly targeted
agents until prospective studies validate CA-125 changes with ob-
jective imaging response results [60, 61]. Specifically, there is a
lack of reliability of CA-125 response criteria with anti-VEGF
molecular therapies, where CA-125 change may not correspond
to imaging response criteria for EOC patients receiving
bevacizumab.
Human epididymis protein 4 (HE4) has been proposed as the
most promising biomarker that may complement CA-125 and
has been approved by the Food and Drug Administration (FDA)
in monitoring the follow-up and relapse of EOC patients.
However, studies are contradictory [62]; as a result, HE4 testing
currently cannot be recommended in routine practice.
Circulating tumour cells (CTCs) and circulating cell-free DNA
(cfDNA) have been used as diagnostic and prognostic markers in
many types of cancer, including ovarian cancer. These techniques
do have specific challenges, including pre-analytical issues
regarding sample volume, the proper tubes for sample collection,
sample storage and the time of the analysis, quality control and
analytical validation of the assays. There are currently no stand-
ard methods for the isolation and detection of either CTCs or
cfDNA in the bloodstream, with few studies recruiting large
cohorts of EOC patients. Further studies regarding the validation,
standardisation and quality control of the assays are needed be-
fore implementing this approach in the clinical routine [63].
Another approach to address this question is the chemotherapy
response score (CRS), which was developed to enable reprodu-
cible and prognostically relevant reporting of the histopatho-
logical changes in interval debulking surgical specimens after
neoadjuvant chemotherapy (NACT) in extrauterine HGSC [64,
65]. Since its description, the CRS has been independently vali-
dated in several studies [66–69], including an individual patient
data meta-analysis incorporating results from over 800 patients
from different centres worldwide [70]. This system has been rec-
ommended for use in the ICCR guidelines for tubal and ovarian
carcinomas [19], since a numerical score allows objective report-
ing and comparison of results and is thus superior to descriptive
reporting (see Table 3). The score identifies the roughly one-third
of all patients (CRS3; total or near-total response) who show sig-
nificantly improved PFS and OS, and has potential for incorpor-
ation into routine practice and clinical trial design as an early end
point.
Recommendation 4.1: the CA-125 criteria for response and
progression as agreed by GCIG have utility in routine practice
but should be used in combination with radiological and clinical
assessment.
Level of evidence: III
Strength of recommendation: A
Consensus: 97.5% (39) yes, 0% (0) no, 2.5% (1) abstain (40
voters)
Recommendation 4.2: the role of CA-125 as a marker of re-
sponse and progression in non-HGSC is less clear.
Level of evidence: V
Strength of recommendation: A
Consensus: 100% (40) yes, 0% (0) no, 0% (0) abstain (40 voters)
Recommendation 4.3: the use of CA-125 in assessing response
and progression to targeted therapies is not yet proven; thus,
radiological and clinical assessment should be used.
Level of evidence: V
Strength of recommendation: A
Consensus: 100% (40) yes, 0% (0) no, 0% (0) abstain (40 voters)
Recommendation 4.4: HE4 should not be used routinely to as-
sess response and progression due to conflicting results.
Level of evidence: IV
Strength of recommendation: A
Consensus: 97.5% (39) yes, 0% (0) no, 2.5% (1) abstain (40
voters)
Table 3. Chemotherapy response score: summary of criteria
CRS Criteria
CRS1: no or minimal
tumour response
Mainly viable tumour with no or minimal regression-associated fibroinflammatory changesa limited to a few foci




Appreciable tumour response amidst viable tumour, both readily identifiable and tumour regularly distributed
Note: cases ranging from multifocal or diffuse regression-associated fibroinflammatory changes,a with viable tumour in sheets,
streaks or nodules, to extensive regression associated fibroinflammatory changesa with multifocal residual tumour which is
easily identifiable
CRS3: total or near-total
tumour response
No residual tumour OR minimal irregularly scattered tumour foci seen as individual cells, cell groups or nodules up to 2 mm in
maximum size
Note: cases showing mainly regression-associated fibroinflammatory changesa or, in rare cases, no/very little residual tumour
in complete absence of any inflammatory response; advisable to record whether ‘no residual tumour’ or ‘microscopic re-
sidual tumour present’
aRegression-associated fibroinflammatory changes: fibrosis associated with macrophages, including foam cells, mixed inflammatory cells and psammoma
bodies; to distinguish from tumour-related inflammation or desmoplasia.
CRS, chemotherapy response score.
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Recommendation 4.5: quantification of circulating cfDNA has
not been established as a tool to assess response and relapse.
Level of evidence: IV
Strength of recommendation: A
Consensus: 97.5% (39) yes, 0% (0) no, 2.5% (1) abstain (40
voters)
Recommendation 4.6: pathological CRS after NACT may pro-
vide an objective and reproducible prognostic measure of out-
come in HGSC.
Level of evidence: IV
Strength of recommendation: A
Consensus: 82.5% (33) yes, 12.5% (5) no, 5% (2) abstain (40
voters)
5. What are the morphological criteria useful in separating
borderline from invasive ovarian neoplasia?
Previously, it was a widely held view that the distinction between
a borderline ovarian tumour (BOT) and a carcinoma was based
on the presence of destructive stromal invasion in the latter.
However, ovarian carcinomas, particularly of mucinous and
endometrioid type, can exhibit expansile (non-destructive) or
infiltrative (destructive) stromal invasion. Mucinous carcino-
mas exhibiting expansile invasion have been reported to have a
lower risk of metastasis than those exhibiting infiltrative inva-
sion [71–76]. Expansile invasion is morphologically character-
ised by complex glandular, papillary and/or cribriform
architecture with a labyrinthine or anastomosing pattern and
little or no intervening stroma [73–75, 77].
Extraovarian disease in association with a serous BOT (sBOT)
was previously divided into non-invasive and invasive implants,
and the former were further divided into ‘epithelial’ and ‘desmo-
plastic’ implants [78]. In the 2014 WHO classification [7], it is
stated that the term extraovarian ‘LGSC’ should be used for in-
vasive implants in association with an sBOT. The WG regards
such terminology as potentially confusing and wishes to separate
bona fide metastases from an ovarian LGSC from invasive
implants in the omentum or peritoneum associated with an
sBOT.
The micropapillary variant of sBOT is characterised by the
presence of slender papillae with a length-to-width ratio of at
least 5:1, growing in a non-hierarchical pattern; a cribriform
growth pattern is less frequent but may co-exist with the micro-
papillary pattern. The micropapillary or cribriform component
must be confluent over an area of at least 5 mm in maximum ex-
tent for the tumour to be designated as a micropapillary variant
of sBOT [78, 79]. The micropapillary variant of sBOT is more
likely to be associated with extraovarian invasive implants than
the typical sBOT, and some advocate using the term ‘non-inva-
sive LGSC’ for the former. This has resulted in this term being
used interchangeably with micropapillary variant of sBOT in the
2014 WHO classification [7]. A recent population-based study of
a Danish cohort with long-term follow-up reported that patients
with micropapillary variant of sBOT are more likely to present at
advanced stage and more frequently have bilateral disease, gross
residual disease after surgery, areas of microinvasion and invasive
implants at presentation, compared with patients with usual-type
sBOT [80]. The WG does not favour the use of the term ‘non-
invasive LGSC’, since such tumours which are confined to the
ovary at presentation have a comparable outcome to usual-type
sBOT and the term may be misleading for clinical management.
There have been various definitions of microinvasion in BOTs
and the 2014 WHO classification [7] uses a cut-off of 5 mm.
Microinvasion can be seen in all morphological subtypes of BOT
but is most common in serous and mucinous neoplasms. Two
types of microinvasion have been described, namely ‘microinva-
sion’ and ‘microinvasive carcinoma’, although the distinction be-
tween these is not always straightforward [81]. Although the
presence of microinvasion has been associated with a higher risk
of tumour recurrence in some series [82], the majority of studies
have not identified such an association [83, 84]. The WG recom-
mends that BOTs with microinvasion should be classified and
managed as borderline tumours.
The term implant should be restricted to extraovarian disease
in association with an sBOT and not be used in the context of a
mucinous BOT (mBOT). Extraovarian disease in a patient with a
presumed mBOT either represents metastasis from an undiag-
nosed or undetected focus of carcinoma within the ovary, or the
ovarian and extraovarian disease represents metastasis from a
mucinous carcinoma elsewhere.
Borderline endometrioid tumours are rare [81]. The criteria
used to distinguish a borderline endometrioid tumour from
endometrioid adenocarcinoma are broadly similar to the criteria
used to distinguish atypical hyperplasia from grade I endome-
trioid adenocarcinoma in the uterine corpus, and are largely
architectural. Adenocarcinomas are characterised by complex
growth with gland fusion and stromal exclusion; cribriform and
microglandular patterns may also be seen [85].
Recommendation 5.1: destructive stromal invasion is no lon-
ger necessary for carcinoma diagnosis (carcinomas may exhibit
expansile invasion).
Level of evidence: V
Strength of recommendation: A
Consensus: 100% (40) yes, 0% (0) no, 0% (0) abstain (40 voters)
Recommendation 5.2: according to the 2014 WHO classifica-
tion, extraovarian invasive implants in association with an sBOT
are synonymous with extraovarian LGSC. The WG does not sup-
port this terminology because it may be misleading for clinical
management.
Level of evidence: V
Strength of recommendation: A
Consensus: 100% (40) yes, 0% (0) no, 0% (0) abstain (40 voters)
Recommendation 5.3: in the 2014 WHO classification, the
micropapillary variant of sBOT is also termed non-invasive
LGSC but the WG does not support this terminology because it
may be misleading for clinical management.
Level of evidence: V
Strength of recommendation: A
Consensus: 100% (40) yes, 0% (0) no, 0% (0) abstain (40 voters)
Recommendation 5.4: microinvasion (<5 mm) can be seen in
borderline tumours but these cases should still be regarded as
borderline for classification and management purposes.
Level of evidence: V
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Strength of recommendation: A
Consensus: 100% (40) yes, 0% (0) no, 0% (0) abstain (40 voters)
Recommendation 5.5: the term implant should not be used in
the context of mBOTs; extraovarian disease in association with a
mBOT should be considered as metastasis (from ovary or another
organ).
Level of evidence: V
Strength of recommendation: A
Consensus: 100% (40) yes, 0% (0) no, 0% (0) abstain (40 voters)
Recommendation 5.6: borderline endometrioid tumours can
be differentiated from grade I endometrioid carcinoma using
similar criteria as used to differentiate atypical hyperplasia from
grade I endometrioid carcinoma in the uterine corpus.
Level of evidence: V
Strength of recommendation: A
Consensus: 97.5% (39) yes, 0% (0) no, 2.5% (1) abstain (40
voters)
Early-stage and borderline tumours
6. Are there exceptions to the standard surgical management for
early-stage ovarian carcinoma?
The standard surgical approach in early-stage ovarian cancer is
based on removal of both ovaries with a staging procedure. A
complete exploration of the abdomino-pelvic peritoneal cavity
via a thorough visual examination is required to detect potential-
ly suspicious implants. Peritoneal staging surgery is based on
peritoneal washing, peritoneal biopsies (pelvic peritoneum, para-
colic gutters, diaphragm) (4–6) and omentectomy (at least infra-
colic). The standard approach is by open surgery. The rationale
for this choice is based on the accuracy of the macroscopic ex-
ploration and the reduction of the risk of a rupture of the primary
tumour during its dissection/removal. This risk is potentially
increased using a minimally invasive surgical approach [86].
Regardless of the approach used, rupture of an intact tumour
could alter the FIGO staging and affect prognosis, and must be
avoided [87]. Nevertheless, the minimally invasive approach can
be considered for restaging surgery in cases when the initial ovar-
ian tumour has been removed and there is no risk of ‘rupture’ of
the ovarian lesion. This surgery should then be carried out by
trained surgeons in expert centres to assure optimal assessment
vision of all abdominal quadrants and to lower the risk of peri-
and post-operative complications. Nodal staging surgery is part
of the ‘conventionally’ required procedure in early-stage ovarian
carcinoma. This nodal staging surgery of apparent stage I ovarian
carcinoma includes a bilateral pelvic and para-aortic lymphade-
nectomy up to the left renal vein (regardless of the surgical ap-
proach used) [88, 89]. Ten to 15% of cases have nodal
involvement [88]. However, due to a low prevalence of nodal
metastases in some histological subtypes (e.g. mucinous carcin-
oma of expansile subtype or LGSC), the indication for staging
surgery in these cases [90–92] may be questioned.
The issue of restaging surgery must be addressed separately.
Contrary to the indication of staging surgery discussed above,
where the decision is based on macroscopic evaluation of the ab-
dominal cavity and the result of a frozen section analysis (FSA),
some patients may have initially undergone surgery without
proper staging. In this context, the restaging procedure is indi-
cated if it may bring new elements that have a direct impact on
the definitive treatment planning. If the primary tumour exhibits
high-risk features (e.g. high-grade, capsule rupture, tubal or peri-
toneal extension) that justify adjuvant chemotherapy, indication
of nodal restaging surgery with the aim of obtaining additional
prognostic variables must be balanced with the potential surgical
morbidity of the procedure.
FSA should be available during a surgical procedure carried
out for a suspicious ovarian mass and should be supported by the
diagnosis of an experienced gynaecological pathologist.
Nevertheless, it must only be done when the surgical strategy
would be altered by the outcome (e.g. choice of a nodal or radical
surgery). FSA is less accurate in cases of pathological diagnosis of
borderline tumours, mucinous tumours, tumour sampling done
by an inexperienced oncologist or large ovarian lesions (>8–
10 cm) [93, 94].
Recommendation 6.1: laparotomy is the standard surgical ap-
proach to treat and stage patients with apparent early-stage ovar-
ian carcinoma.
Level of evidence: V
Strength of recommendation: A
Consensus: 100% (40) yes, 0% (0) no, 0% (0) abstain (40 voters)
Recommendation 6.2: minimally invasive surgery can be car-
ried out for restaging.
Level of evidence: IV
Strength of recommendation: B
Consensus: 75% (30) yes, 12.5% (5) no, 12.5% (5) abstain (40
voters)
Recommendation 6.3: whatever the approach used, rupture of
an intact tumour with spillage of cancer cells at the time of sur-
gery must be avoided.
Level of evidence: IV
Strength of recommendation: A
Consensus: 100% (40) yes, 0% (0) no, 0% (0) abstain (40 voters)
Recommendation 6.4: peritoneal restaging surgery is manda-
tory even if it does not alter the indication for adjuvant
chemotherapy.
Level of evidence: V
Strength of recommendation: B
Consensus: 92.5% (37) yes, 2.5% (1) no, 5% (2) abstain (40
voters)
Recommendation 6.5: peritoneal restaging should be consid-
ered in cases of incidentally detected, apparently isolated STIC
lesions.
Level of evidence: IV
Strength of recommendation: B
Consensus: 100% (40) yes, 0% (0) no, 0% (0) abstain (40 voters)
Recommendation 6.6: the standard surgical staging of appar-
ent early EOC includes systematic lymph node (LN) dissection of
the pelvic and the para aortic regions up to the left renal vessel
origin.
Level of evidence: IV
Strength of recommendation: A
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Consensus: 77.5% (31) yes, 22.5% (9) no, 0% (0) abstain (40
voters)
Recommendation 6.7: LN dissection for restaging purposes
may be avoided if the nodal status does not alter the patient
management.
Level of evidence: V
Strength of recommendation: B
Consensus: 95% (38) yes, 0% (0) no, 5% (2) abstain (40 voters)
7. What are the limits of fertility-sparing surgery (cancer and bor-
derline ovarian tumour)?
Fertility-sparing surgery (FSS) is based on unilateral salpingo-
oophorectomy and complete surgical staging. This management
seems to be safe in patients with conventional low-grade stage IA
(serous, endometrioid or mucinous expansile subtype) [95–97].
The use of FSS in patients with stage IC disease should be defined
using the current 2014 FIGO staging system [98]. FSS is accept-
able for stage IC1 tumours, with half of these recurrences being
isolated on the remaining ovary and therefore able to be rescued
by subsequent surgery. However, the recurrence rates are higher
in stage IC2, IC3 and grade 3 disease, although mainly in extrao-
varian sites and are, therefore, not clearly correlated with the
fertility-sparing approach. Adequate counselling is, therefore,
needed in this situation [98].
In cases of stage II or III disease, the use of FSS is unconven-
tional, with high risk of recurrences reported [95]. FSS remains
contraindicated in these patients, although it is unclear whether
such recurrences are related to the natural history of the disease
rather than the type of surgery in these ‘high-risk’ patients.
Recommendation 7.1: FSS can be safely offered to all stage IA
and IC1 low-grade ovarian carcinomas.
Level of evidence: IV
Strength of recommendation: B
Consensus: 94.7% (36) yes, 2.6% (1) no, 2.6% (1) abstain (38
voters)
Recommendation 7.2: there is no place for ovarian preserva-
tion for invasive EOC greater than fully staged FIGO stage I.
Level of evidence: V
Strength of recommendation: A
Consensus: 94.9% (37) yes, 0% (0) no, 5.1% (2) abstain (39
voters)
8. Should all stage I carcinomas receive adjuvant chemotherapy
and, if not, which ones?
A Cochrane systematic review [99] clearly demonstrated that the
addition of adjuvant platinum-based chemotherapy to surgery is
effective in significantly prolonging long-term OS and PFS in
women with early-stage EOC. Considering the risk of recurrence,
the ICON1 trial [100–103] determined that women with a high-
risk of recurrence (stage IA grade 3, IB or IC grade 2 or 3, any
clear cell tumours) may benefit the most from adjuvant chemo-
therapy. Retrospective studies [104–107] suggested that adjuvant
chemotherapy may not be necessary for some histological sub-
groups, due to the absence of recurrences observed in patients
who did not receive adjuvant chemotherapy. It should be noted
that the ICON1 trial [100–103] could neither confirm nor
exclude survival benefits in low/intermediate risk disease (stage IA
grade 1 or 2, IB or IC grade 1) in a subgroup analysis. Recently, the
retrospective SEER database also reported no benefit for adjuvant
chemotherapy in the low and intermediate endometrioid groups
[108]. On the contrary, in a large cohort study [109], chemother-
apy was associated with reduced mortality not only for high-risk
patients but also for patients with stage IA/IB, grade 2 ovarian can-
cer. This study was in line with prior study results demonstrating
no benefit for chemotherapy in women with stage IA and IB, grade
1 neoplasms. Finally, the available data could neither confirm nor
exclude survival benefits for the addition of adjuvant chemother-
apy in optimally staged patients (all risk groups considered).
More specifically, for histological subgroups such as clear cell car-
cinoma, the targeted retrospective studies reported in the litera-
ture primarily from Asian populations [105, 107, 108, 110] did
not identify any benefit compared with observation for early-stage
disease (stage IA to IC1). For the mucinous subgroup, the expan-
sile or grade I type is associated with better prognosis and should
not receive adjuvant chemotherapy, while the infiltrative form is
associated with a high risk of relapse [72, 90, 91, 111].
The chemotherapy administered in the ICON1 [100–103] and
ACTION [112–116] trials consisted of a variety of platinum-
based regimens, given ideally for 6 cycles. However, only 4 cycles
were required for the ACTION trial and only half of the patients
in the ICON1 trial received all 6 cycles without dose modification,
due to toxicity. Bell et al. [117] reported an RCT of 3 versus 6
cycles of adjuvant carboplatin and paclitaxel administered every
3 weeks in women with high-risk, early-stage ovarian cancer. This
GOG trial found that longer treatment was not associated with
significant reduction in recurrence risk and resulted in additional
toxicity. A subsequent exploratory analysis [118] of this GOG
study revealed that longer adjuvant therapy was associated with a
significant reduction in recurrence risk for serous tumours but
not for non-serous tumours. There was no benefit for longer adju-
vant therapy in any other subgroup of interest, including age, per-
formance status (PS), stage, grade and presence of ascites, tumour
rupture and positive cytology. Bakkum-Gamez et al. [119] eval-
uated a cohort of surgically staged, stage I ovarian cancer patients
who completed either 3 or 6 cycles of carboplatin and paclitaxel.
Patients with stage IC cancer and with fixed tumours (described
adhesions or fixation to other pelvic structures) and positive cy-
tology and/or tumour surface involvement appeared to have a
lower risk of recurrence after 6 cycles of carboplatin/paclitaxel
compared with 3 cycles, although the cohort is recognisably small.
Four trials [100–103, 112–116, 120–122] included in the
Cochrane systematic review [99] mentioned above used
cisplatin-based chemotherapy, while one [123] used melphalan.
Six percent of women in the combined ACTION/ICON1 trials
[100–103, 112–116] and none of the women in the other trials
making up this meta-analysis received taxanes. The majority of
women received carboplatin monotherapy (about 6 out of 10
patients in ACTION/ICON1 trials [100–103, 112–116] and all of
the women included in the trial published by Tropé et al. [121,
122]). The others received either cisplatin or cisplatin combina-
tions. As part of the ICON3 trial [124] comparing carboplatin
with carboplatin plus paclitaxel, 20% of the population actually
had stage I or II disease. There was no benefit in survival for the
use of carboplatin plus paclitaxel either in the trial as a whole or
in the women with early-stage disease, with >80% of patients
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receiving 6 cycles of chemotherapy. The GOG 175 trial [125]
demonstrated that adding 24 weeks of weekly maintenance low-
dose paclitaxel to the standard 3 cycles of carboplatin plus pacli-
taxel did not significantly impact recurrence-free interval in
patients with completely resected, high-risk, early-stage ovarian
cancer and is associated with increased toxicity.
The potential importance of the timing of initiation of adju-
vant therapy after surgery has been studied in patients with ovar-
ian cancer [126–136]. However, all of these published studies
except one [137] pertain to advanced disease or had a higher pro-
portion of stage III–IV patients. Although this one report [137]
of early-stage ovarian cancer patients from two RCTs (GOG 95
[138] and GOG 157 [117]) did not identify a benefit associated
with earlier initiation of adjuvant therapy, it remains unclear if a
significant delay in starting adjuvant therapy may worsen out-
come. In conclusion, adjuvant chemotherapy should be based on
decision-making treatment algorithms (see Figures 1–4).
Platinum-based monotherapy or combination chemotherapy
can be given. Optimal duration remains controversial; however,
serous tumours should receive 6 cycles.
Recommendation 8.1: adjuvant chemotherapy should be
offered to patients with early-stage ovarian cancer (stage I–IIA)
with the exception of fully staged patients with the following:
• Low-grade serous IA
• Grade 1 and 2 endometrioid IA
• Grade 1 and 2 mucinous IA (expansile invasion)
Level of evidence: II
Strength of recommendation: A
Consensus: 100% (40) yes, 0% (0) no, 0% (0) abstain (40 voters)
Recommendation 8.2: adjuvant chemotherapy is not recom-
mended in the management of incidentally detected isolated
STIC lesions.
Level of evidence: V
Strength of recommendation: A
Consensus: 100% (40) yes, 0% (0) no, 0% (0) abstain (40 voters)
Recommendation 8.3: the benefit of adjuvant chemotherapy is
uncertain for patients with the following cancers and should be
discussed on an individual patient basis:
• Clear cell carcinoma stage IA and IB/IC1
• Grade 1 and 2 endometrioid IB/IC
• Low-grade serous IB/IC
• Grade 1 and 2 mucinous IC (expansile invasion)
• Mucinous IA (infiltrative invasion)
Level of evidence: III
Strength of recommendation: C
Consensus: 92.5% (37) yes, 7.5% (3) no, 0% (0) abstain (40
voters)
Recommendation 8.4: for patients with early-stage disease




Level of evidence: I (carboplatin alone), II (carboplatin/
paclitaxel)
Strength of recommendation: A
Consensus: 100% (40) yes, 0% (0) no, 0% (0) abstain (40 voters)
Recommendation 8.5: for patients receiving single-agent adju-
vant carboplatin, 6 cycles are recommended.
Level of evidence: I
Strength of recommendation: A
Consensus: 100% (40) yes, 0% (0) no, 0% (0) abstain (40 voters)
Recommendation 8.6: for patients receiving carboplatin and
paclitaxel, a minimum of 3 cycles is recommended except for the
Serous histology
Stage IA
Low grade Low grade Low gradeHigh grade High grade High grade

















Figure 1. Adjuvant chemotherapy for patients with early-stage serous ovarian cancer (stage I–IIA).
aConsidered no adjuvant chemotherapy only for patients with complete surgical staging.
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high-grade serous subgroup or stage IC (any histological type),
for whom 6 cycles are recommended.
Level of evidence: II
Strength of recommendation: B
Consensus: 77.5% (31) yes, 0% (0) no, 22.5% (9) abstain (40
voters)
9. Are non-serous borderline ovarian tumours managed accord-
ing to the same standard as serous borderline ovarian tumours?
FSS (defined as the preservation of the uterus and at least a part of
one ovary) is the standard management of young patients with
BOTs [139, 140] while bilateral salpingo-oophorectomy with or
without hysterectomy is the standard management of BOTs in
menopausal patients. Focussing on the risk factors for overall
recurrences (borderline and invasive) for all patients, conserva-
tive treatment (and particularly cystectomy) and incompletely
staged disease increased the rate of relapse [83]. Nevertheless,
those factors did not exert a statistical impact on the invasive re-
currence rate because most of the recurrences were borderline
tumours, which are unlikely to have a further impact on patient
outcomes [140, 141]. The risk of an invasive recurrence is very
low but exists, and is estimated at 0.5% after FSS [142]. Even
when preservation of healthy ovarian tissue is not technically
‘feasible’ (bulky bilateral involvement of ovaries), preservation of
the uterus should be considered.
The impact of the histological subtype on surgical manage-
ment (mBOT or sBOT) is still debated [83, 142, 143]. Patients
with mBOTs relapse less frequently than those with serous dis-
ease, but when a relapse occurs, the risk of an invasive recur-
rence seems to be higher for mBOTs [144]. Nevertheless, clear
evidence is lacking as to whether this is due to the particular
natural history of this tumour, to a wider use of cystectomy or
to the fact that, as mBOT may be bulky, a small part of a ‘true’
invasive carcinoma may have been misdiagnosed after the ini-
tial sampling of a large tumour [144]. Pragmatically, as most
mBOTs are unilateral, unilateral salpingo-oophorectomy is rec-
ommended to decrease the potential risk of invasive recurrence
[142, 144].
Clear cell histology
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Figure 3. Adjuvant chemotherapy for patients with early-stage clear cell ovarian cancer (stage I–IIA).
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Figure 2. Adjuvant chemotherapy for patients with early-stage mucinous ovarian cancer (stage I–IIA).
aConsidered no adjuvant chemotherapy only for patients with complete surgical staging.
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The case of serous disease is somewhat different because bilat-
eral tumours are observed in 15%–25% of cases and peritoneal
spread in 15%–40% [145]. A meta-analysis and a large multi-
centre German series demonstrated that (ultraconservative) sur-
gery (cystectomy) increases the risk of recurrence [139, 141].
Nonetheless, this does not imply that an adnexectomy should be
preferred over a cystectomy because the use of this latter proced-
ure also increases the subsequent fertility rate [146]. A recent
phase III trial (the only one concerning BOTs in the ‘modern
era’) demonstrated that the use of bilateral cystectomies com-
pared with a unilateral adnexectomy and a contralateral cystec-
tomy (in patients with bilateral BOTs, mainly in serous subtype)
increased the fertility rate without increasing the recurrence rate
[146]. Moreover, the risk of ovarian invasive recurrence is very
low in stage I serous disease [144]. Preservation of the maximum
volume of the healthy ovary (and follicles) should, therefore, be
proposed to improve fertility results. Cystectomy is an acceptable
management in sBOTs to optimise fertility preservation.
Recommendation 9.1: preservation of at least part of one ovary
and the uterus is the standard approach in young patients with
BOTs.
Level of evidence: III
Strength of recommendation: A
Consensus: 100% (40) yes, 0% (0) no, 0% (0) abstain (40 voters)
Recommendation 9.2: unilateral salpingo-oophorectomy is
recommended with mBOTs to decrease the risk of invasive recur-
rence after cystectomy.
Level of evidence: IV
Strength of recommendation: A
Consensus: 100% (40) yes, 0% (0) no, 0% (0) abstain (40 voters)
Recommendation 9.3: cystectomy is an acceptable manage-
ment in sBOTs to preserve fertility.
Level of evidence: III
Strength of recommendation: B
Consensus: 100% (40) yes, 0% (0) no, 0% (0) abstain (40 voters)
10. How should serous borderline ovarian tumours with
extraovarian implant be managed?
Adequate staging in BOTs includes careful inspection of the peri-
toneum and peritoneal staging biopsies as previously described.
Appendectomy as a staging procedure is not recommended even
in the mucinous subtype [147]. There is no evidence supporting
LN dissection. Large studies have demonstrated that the omission
of staging has an impact on recurrence rate [83]. On the other
hand, the benefit on OS of complete surgical staging in macro-
scopically stage I BOTs remains unproven [148, 149]. The benefit
of restaging surgery is questionable if comprehensive staging has
not been completed during the first surgery. Considering the po-
tential morbidity associated with this procedure, surgical restag-
ing should only be considered in the following situations: (i)
patients with a higher risk of extraovarian microscopic implants
(serous tumour with micropapillary patterns) or (ii) patients
with incomplete visual exploration of the abdomino-pelvic peri-
toneum during the first surgery.
In the case of sBOTs with peritoneal implants, residual disease
has been reported to be a prognostic factor [142, 150, 151].
Complete removal of peritoneal implants is necessary for both stag-
ing and therapeutic purposes. There is no proven benefit of lym-
phadenectomy in stage II/III sBOTs [142]. Data in the literature
concerning FSS in sBOTs with peritoneal implants are rare [140,
145]. Compared with stage I disease treated conservatively, the risk
of recurrence is increased after conservative treatment of more
advanced stages [145]. These could be ovarian and/or peritoneal
and so not related to the ovarian preservation itself but to the nat-
ural history of the initial peritoneal spread [145]. Furthermore, the
risk of lethal outcomes is rare in this context if a complete resection
of implants is achieved [145]. FSS could be then considered in
selected stage II or III sBOTs. Some authors have suggested to ex-
tend this strategy even in the cases of invasive implants [140]; how-
ever, less than 15 cases have been reported [140, 145].
The role of adjuvant chemotherapy in advanced-stage sBOTs is
highly debated [152, 153]. Recent retrospective data, collecting
the largest number to date of patients with invasive implants
treated with surgery and adjuvant chemotherapy, suggested a
Endometrioid histology
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Figure 4. Adjuvant chemotherapy for patients with early-stage endometrioid ovarian cancer (stage I–IIA).
aConsidered no adjuvant chemotherapy only for patients with complete surgical staging.
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potential advantage in selected groups of patients [152].
According to the available evidence, there is no benefit in adding
adjuvant treatment to upfront surgery in patients with sBOTs
with invasive implants [111, 151–171]. A meta-analysis on BOTs
concluded that there is no evidence supporting the use of any spe-
cific type of adjuvant treatment [153]. However, considering the
low risk of invasive high-grade relapse, it is unlikely that it will be
possible to demonstrate the efficacy of adjuvant treatment in
these patients.
It is important to note that sBOTs with invasive implants
would be now defined as ‘extraovarian LGSC’ according to the
2014 WHO classification [7]. Since the management of young
patients with sBOTs is clearly different than stage II/III LGSC
(in terms of FSS in young patients, place of LN dissection or ad-
juvant treatment strategies), patients with sBOTs and invasive
implants must be considered as a separate entity from advanced
LGSC.
Recommendation 10.1: peritoneal staging surgery is recom-
mended for sBOTs.
Level of evidence: III
Strength of recommendation: B
Consensus: 100% (40) yes, 0% (0) no, 0% (0) abstain (40 voters)
Recommendation 10.2: the benefit of restaging is not clear but
should be considered in patients with:
• sBOTs with micropapillary pattern
• sBOTs with incomplete visual exploration of the peritoneal
cavity
Level of evidence: IV (sBOTs with micropapillary pattern), III
(sBOTs with incomplete visual exploration of the peritoneal
cavity)
Strength of recommendation: B
Consensus: 100% (40) yes, 0% (0) no, 0% (0) abstain (40 voters)
Recommendation 10.3: there is no role for appendectomy in
BOTs.
Level of evidence: V
Strength of recommendation: A
Consensus: 85% (34) yes, 0% (0) no, 15% (6) abstain (40 voters)
Recommendation 10.4: all peritoneal implants must be
removed.
Level of evidence: IV
Strength of recommendation: A
Consensus: 100% (40) yes, 0% (0) no, 0% (0) abstain (40 voters)
Recommendation 10.5: there is no proven benefit of systematic
LN dissection in stage II/III sBOTs.
Level of evidence: IV
Strength of recommendation: B
Consensus: 97.5% (39) yes, 0% (0) no, 2.5% (1) abstain (40
voters)
Recommendation 10.6: FSS could be considered in selected
patients with stage II or III sBOTs.
Level of evidence: V
Strength of recommendation: B
Consensus: 100% (40) yes, 0% (0) no, 0% (0) abstain (40 voters)
Recommendation 10.7: adjuvant systemic treatment is not rec-
ommended for primary treatment of sBOTs with extraovarian
invasive/non-invasive implants.
Level of evidence: III
Strength of recommendation: B
Consensus: 92.5% (37) yes, 0% (0) no, 7.5% (3) abstain (40
voters)
Advanced-stage disease
11. How to select patients for primary debulking surgery or
neoadjuvant chemotherapy?
Complete resection of all macroscopic disease has been shown to
be the single most important independent prognostic factor in
advanced EOC [172, 173] and careful evaluation of patients be-
fore surgery is essential to defining the management plan [174]. If
resection of all macroscopic disease can be obtained based on
pre-operative staging with an acceptable operative morbidity, up-
front debulking surgery (UDS) followed by carboplatin/paclitaxel
is standard of care [175, 176]. The EORTC55971 trial [177] and
the CHORUS trial [178] showed a similar PFS and OS for
patients with stage IIIC or IV disease receiving NACT and inter-
val debulking surgery (IDS) compared with UDS. As both studies
contained low percentages of patients with complete UDS
(<20%), the Trial on Radical Upfront Surgical Therapy
(TRUST), including a qualification process for participating
centres, is currently ongoing.
Nevertheless, evidence-based standardisation of the assessment
of disease extent and patient condition are essential to predict the
possibility of residual macroscopic disease after UDS [179]. Pre-
operative diagnostic work-up with computed tomography (CT),
positron emission tomography (PET)-CT, or diffusion-weighted
whole-body magnetic resonance imaging (MRI), should be used
to assess the extent of disease [180–183]. Ultrasound imaging
quality has improved in recent decades; if carried out by an expe-
rienced sonographer, ultrasound has an invaluable role in esti-
mating the malignant potential and histopathological features of
ovarian cysts but also in assessing tumour extent in the pelvis and
abdominal cavity [184–186]. Diagnostic laparoscopy can provide
a definitive histopathological diagnosis and detailed information
about the intra-abdominal disease burden (e.g. Fagotti scoring
system) [187, 188]. After laparoscopy, a high rate of port-site
metastases are observed, but do not worsen the prognosis [189].
Based on previously described examinations, in 2017 ESGO
formulated recommendations on contraindications to UDS
related to tumour spread [190]. Patient-specific factors (e.g. co-
existing illnesses, age, WHO PS) should also be considered in the
pre-operative assessment of operability [174, 179]. To assure ad-
equate management of patients with HGSC, diagnostic work-up
as well as the treatment should be carried out in a multidisciplin-
ary setting and in a specialist ovarian cancer centre, according to
ESGO Quality recommendations 2016 [191].
Recommendation 11.1: the selection of patients for primary
debulking surgery or neoadjuvant treatment must be carried out
in a specialist ovarian cancer centre, according to the ESGO
Quality recommendations 2016 [191] in a multidisciplinary
setting.
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Level of evidence: IV
Strength of recommendation: A
Consensus: 100% (40) yes, 0% (0) no, 0% (0) abstain (40 voters)
Recommendation 11.2: complete tumour resection at upfront
debulking is the most important prognostic factor for patients
with advanced ovarian cancer and is the main goal of surgery.
Level of evidence: IV
Strength of recommendation: A
Consensus: 100% (40) yes, 0% (0) no, 0% (0) abstain (40 voters)
Recommendation 11.3: when complete surgery with no
macroscopic visible disease appears feasible (both spread of dis-
ease and general condition of the patient), primary upfront
debulking should be offered.
Level of evidence: IV
Strength of recommendation: B
Consensus: 100% (40) yes, 0% (0) no, 0% (0) abstain (40 voters)
Recommendation 11.4: diagnostic work-up with CT, PET-CT
or diffusion-weighted whole-body MRI and expert ultrasound or
diagnostic laparoscopy should be used to assess the extent of
disease.
Level of evidence: III
Strength of recommendation: C
Consensus: 100% (40) yes, 0% (0) no, 0% (0) abstain (40 voters)
Recommendation 11.5: patients are not candidates for
primary surgery (according to ESGO 2017 recommendations
[190]) if the following spread of disease, among other factors, is
present:
• Diffuse deep infiltration of the root of small bowel mesentery
• Diffuse carcinomatosis of the small bowel involving such
large parts that resection would lead to a short bowel syn-
drome (remaining bowel <1.5 m)
• Diffuse involvement/deep infiltration of:
8 stomach/duodenum
8 head or middle part of pancreas
• Involvement of coeliac trunk, hepatic arteries, left gastric
artery
• Central or multisegmental parenchymal liver metastases




Level of evidence: III
Strength of recommendation: A
Consensus: 100% (40) yes, 0% (0) no, 0% (0) abstain (40 voters)
12. What is the current role of bevacizumab in first-line treatment?
Bevacizumab was the first targeted therapy to receive the approv-
al of the European Medicines Agency (EMA) for the treatment of
EOC in the first-line and relapsed settings. GOG 218 [192], a
placebo-controlled phase III trial, randomised patients with in-
completely resected stage III or any stage IV newly diagnosed
EOC to either carboplatin/paclitaxel with or without bevacizu-
mab (15 mg/kg) followed by placebo or bevacizumab mainten-
ance treatment up to 21 cycles; significant increase in PFS was
shown in patients receiving bevacizumab for 21 cycles. The
ICON7 trial [193] included patients with high-risk, early-stage
disease (stage I or IIA and clear cell or grade 3 tumours) or
advanced-stage IIB to IV tumours. Despite lower dosage and
fewer cycles of bevacizumab (7.5 mg/kg for 18 cycles) used in the
ICON7 trial, PFS results were similar [193]. Neither the GOG 218
trial nor the ICON7 trial showed an OS benefit in the overall
study populations [192, 193] but post hoc subgroup analysis
indicated statistically significant OS benefit in patients with stage
IV disease in GOG 218 [194] and patients at high risk of progres-
sion (i.e. FIGO stage III with >1 cm residual disease or stage IV)
in the ICON7 trial [22].
Bevacizumab-related toxicities are usually mild. The most
common toxicities aregrade 2 hypertension andgrade 3 pro-
teinuria. The incidence is positively correlated with higher dose
and longer duration [192, 193]. Furthermore, the ICON7 and
GOG 218 trials showed a trend towards more mucocutaneous
bleeding, grade 3 thromboembolic events and gastrointestinal
adverse events (AEs) [192, 193, 195]. Regarding gastrointestinal
toxicity, the most common AE was perforation (1.1%), followed
by haemorrhage (0.8%) and fistula formation (0.7%) [22, 195].
Multivariable analysis estimated that previous treatment of in-
flammatory bowel disease and large bowel resections at UDS are
significantly associated with increased odds of gastrointestinal
AEs [195]. Adequate patient selection is important to minimise
the occurrence of these serious AEs.
Recently, the results of the SOLO1 trial were presented and
showed the importance of the use of PARP inhibition after first-
line chemotherapy in BRCA-mutated patients (without the use of
bevacizumab) [33]. This phase III trial demonstrated a 70% risk
reduction of disease progression or death with olaparib mainten-
ance therapy after complete or partial response on first-line
standard, platinum-based chemotherapy in patients with newly
diagnosed, advanced BRCA-mutated ovarian cancer.
Regarding the administration of bevacizumab with NACT, two
smaller RCTs, the ANTHALYA and GEICO 1205/NOVA open-
label phase II trials [196, 197], were carried out. Patients received
4 cycles of neoadjuvant carboplatin/paclitaxel with or without at
least 3 cycles of bevacizumab (15 mg/kg) followed by IDS [196,
197]. Bevacizumab was stopped 4–5 weeks before surgery and
restarted at least 7 weeks after IDS in the ANTHALYA trial [196],
compared with 6 weeks before and 6 weeks after surgery in the
GEICO 1205/NOVA trial [197]. In the ANTHALYA trial [196],
complete resection rate (CRR) was significantly higher with add-
itional bevacizumab compared with CRR previously reported in
the EORTC study [177]. In contrast, the GEICO 1205/NOVA
trial [197] showed no benefit in the complete macroscopic re-
sponse rate (PCI¼ 0) but found an enhanced rate of surgical op-
erability. Both studies showed similar safety profiles, with no
increase in toxicity (grade 3 haematological, gastrointestinal
and vascular AEs) compared with carboplatin/paclitaxel therapy
when adequate patient selection was carried out. Therefore, beva-
cizumab in the neoadjuvant setting is considered safe and may
improve surgical outcome.
Recommendation 12.1: bevacizumab (15 mg/kg or 7.5 mg/kg
every 3 weeks for maximum of 15 months) improves PFS in
patients with stage III–IV ovarian cancer and should be consid-
ered in addition to carboplatin and paclitaxel.
Level of evidence: I
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Strength of recommendation: A
Consensus: 97.5% (39) yes, 0% (0) no, 2.5% (1) abstain (40
voters)
Recommendation 12.2: bevacizumab in the neoadjuvant set-
ting can be considered, although additional improvement in effi-
cacy is not proven with level I evidence.
Level of evidence: II
Strength of recommendation: B
Consensus: 97.5% (39) yes, 2.5% (1) no, 0% (0) abstain (40
voters)
Recommendation 12.3: bevacizumab can be safely administered
in the neoadjuvant setting before and after IDS providing the inter-
val between surgery and administration is at least 4–6 weeks.
Level of evidence: II
Strength of recommendation: B
Consensus: 100% (40) yes, 0% (0) no, 0% (0) abstain (40 voters)
13. Should weekly regimens be used in first line?
The JGOG 3016 trial [198], carried out in Japan, was the first
multicentre RCT comparing first-line treatment with 3-weekly
carboplatin (AUC6) and paclitaxel (180 mg/m2) with a dose-
dense regimen of 3-weekly carboplatin and weekly paclitaxel
(80 mg/m2). This showed improved PFS and OS rates but higher
toxicity with the dose-dense regimen [198]. In contrast, GOG
262 [199] (a multicentre phase III RCT) could not confirm this
survival benefit despite using a similar study protocol. When
patients did not receive bevacizumab, a subgroup analysis of the
GOG 262 trial showed a significant increase in PFS in favour of
weekly paclitaxel compared with 3-weekly. When receiving beva-
cizumab, no differences in PFS were shown [199]. As this sub-
group analysis was not preplanned and only carried out on 16%
of the study population, weekly paclitaxel should not be regarded
as a substitution for bevacizumab.
MITO-7, a multicentre open-label phase III RCT [200], was
the first trial to compare 3-weekly carboplatin (AUC6) and pacli-
taxel (175 mg/m2) with weekly administration of carboplatin
(AUC2) and paclitaxel (60 mg/m2). The weekly schedule showed
similar survival rates but significantly better quality of life (QoL)
(co-primary end point) with lower rates of grade 3 neutropae-
nia, febrile neutropaenia, grade 3 thrombocytopaenia, grade
2 neuropathy and alopecia. Van der Burg et al. [201] randomised
patients to NACT with either weekly carboplatin (AUC4)/weekly
cisplatin (70 mg/m2) and weekly paclitaxel (90 mg/m2) or 3-
weekly carboplatin (AUC6)/cisplatin (75 mg/m2) and paclitaxel
(175 mg/m2) and found similar response rates, PFS and OS be-
tween both groups [201]. In contrast to the MITO-7 trial [200],
(non)haematological toxicities were more frequent in the weekly
schedule, probably caused by the higher dose intensity of plat-
inum [cisplatin (40% of patients) or carboplatin] and higher
doses of paclitaxel.
The first results of the ICON8 trial [202] were presented at the
ESMO 2017 Congress. As part of this trial, patients were rando-
mised into three treatment arms: (i) 3-weekly carboplatin
(AUC5/6) and weekly paclitaxel (80 mg/m2); (ii) both weekly car-
boplatin (AUC2) and paclitaxel (80 mg/m2) and (iii) standard 3-
weekly carboplatin (AUC5/6) and paclitaxel (175 mg/m2). The
use of weekly scheduling in first-line treatment of EOC did not
extend PFS, but, in contrast to the MITO-7 trial [200], no de-
crease in toxicity was seen (again, higher doses of paclitaxel were
used) [202]. Therefore, weekly carboplatin/paclitaxel according
to the MITO-7 schedule is an alternative to the 3-weekly schedule
in Caucasian patients.
Recommendation 13.1: incorporation of weekly chemother-
apy into first-line treatment for women with EOC does not im-
prove PFS or OS in the population of western countries.
Level of evidence: I
Strength of recommendation: A
Consensus: 100% (40) yes, 0% (0) no, 0% (0) abstain (40 voters)
Recommendation 13.2: the schedule of weekly chemotherapy
with carboplatin (AUC2) and paclitaxel (60 mg/m2) shows better
QoL and reduced toxicity (e.g. alopecia, neuropathy) compared
with the standard 3-weekly schedule and can be considered.
Level of evidence: I
Strength of recommendation: B
Consensus: 95% (38) yes, 0% (0) no, 5% (2) abstain (40 voters)
Recommendation 13.3: weekly chemotherapy cannot be
regarded as a substitute for bevacizumab.
Level of evidence: V
Strength of recommendation: B
Consensus: 100% (40) yes, 0% (0) no, 0% (0) abstain (40 voters)
Recommendation 13.4: 3-weekly carboplatin/paclitaxel
remains the standard-of-care chemotherapy of first-line ovarian
cancer treatment.
Level of evidence: I
Strength of recommendation: A
Consensus: 100% (40) yes, 0% (0) no, 0% (0) abstain (40 voters)
14. Is there a place for intraperitoneal chemotherapy and
hyperthermic intraperitoneal chemotherapy?
Several studies have been published, but due to their small sample
size, incomparable treatment protocols and high levels of tox-
icity, intraperitoneal (i.p.) chemotherapy was not recommended
for routine use [203–206]. The GOG 172 trial randomised
patients with stage III disease to either 3-weekly intravenous (i.v.)
cisplatin/paclitaxel or i.v. paclitaxel followed by i.p. cisplatin/
paclitaxel and showed a remarkable improvement in OS [207]
persisting even after 10 years [208]. Despite these promising
results, toxicity with i.p. (e.g. grade 3–4 leukopaenia, gastrointes-
tinal/renal AEs, infection and pain) was significantly higher with
lower QoL and a lower completion rate [207] for 6 i.p. cycles
compared with previous reported studies [203, 204]. Moreover,
the absence of an ITT analysis, the higher dosage of paclitaxel/cis-
platin in the i.p. arm, the imbalance in PFS/OS benefit ratio and
the low OS in the control group compared with published data
[209, 210] further limit the clinical relevance and implementation
of i.p. therapy in ovarian cancer [211]. To address the pitfalls of
the GOG 172 trial, a phase III RCT (GOG 252) [212] was carried
out on patients with stage II–IV EOC. As the first trial comparing
i.p. and i.v. administration of similar doses of chemotherapy, the
GOG 252 trial [212] did not confirm PFS improvement with i.p.
chemotherapy (presented at SGO 2016, still unpublished).
Moreover, i.v. chemotherapy was better tolerated than i.p.
chemotherapy.
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The only RCT on the effect of hyperthermic intraperitoneal
chemotherapy (HIPEC) in recurrent EOC has been widely
criticised [212–215], and a meta-analysis [216] of retrospective
studies in advanced or recurrent EOC did not show any survival
advantage but rather an increase in AEs (e.g. anaemia, acute kid-
ney injury) [217, 218], precluding HIPEC from standard-of-care
treatment. A recently published multicentre open-label phase III
trial (OVHIPEC) [219] randomised patients with stage III EOC
with abdominal disease too extensive for UDS or after UDS with
residual disease >1 cm, and after response to 3 cycles of NACT,
to undergo IDS with or without HIPEC (cisplatin 100 mg/m2).
The addition of HIPEC to IDS resulted in a significantly longer
PFS and OS without increasing toxicity. However, as all stage IV
patients were excluded and the majority of stage III patients could
be primarily debulked to <1 cm [220–223], only a very small
group of EOC patients with advanced disease fulfilled the criteria
of inclusion, explaining the slow recruitment but also rendering
extrapolation of these results to all patients with advanced disease
impossible. Moreover, as OS was not a primary/co-primary end
point, the small study size can induce significant bias, giving a
possible explanation for the imbalance in PFS/OS improvement
ratio [222]. Furthermore, stratification was lacking for important
prognostic factors like BRCA status, FIGO subclassification, re-
sponse rates to NACT and histological type [222, 223]. Lastly,
HIPEC toxicity appeared to be underreported as toxicity was
reported equally in both study arms despite longer operation
times, longer hospitalisation periods, more perioperative gastro-
stomies/stomas and vague reports on known AEs (e.g. acute renal
failure) when receiving HIPEC [222–225].
At the ASCO 2017 Congress, Lim et al. [217] presented another
trial including patients with stage III and IV ovarian cancer ran-
domly allocated to the HIPEC arm (cisplatin 75 mg/m2, 90 min)
or a control arm (no HIPEC) intraoperatively based on residual
tumour (size<1 cm). The survival analysis did not show the stat-
istical superiority of the HIPEC arm. Considering these concerns,
HIPEC might provide additional survival benefit in EOC, but
large prospective studies are required to further quantify the true
efficacy of HIPEC and to compare its efficacy and compatibility
with targeted therapy (e.g. bevacizumab). In the meanwhile,
HIPEC should not be considered as standard therapy and be lim-
ited to well-designed prospective RCTs.
Recommendation 14.1: i.p. chemotherapy is not a standard of
care as first-line treatment.
Level of evidence: I
Strength of recommendation: A
Consensus: 95% (38) yes, 0% (0) no, 5% (2) abstain (40 voters)
Recommendation 14.2: HIPEC is not a standard of care as
first-line treatment.
Level of evidence: II
Strength of recommendation: A
Consensus: 95% (38) yes, 0% (0) no, 5% (2) abstain (40 voters)
15. Is the standard of management of non-high-grade serous EOC
different?
Similar to HGSC, optimal surgical treatment is the keystone of
the treatment of advanced low-grade serous ovarian cancer [172,
226]. Regarding the less chemosensitive nature of low-grade ser-
ous ovarian cancer, even debulking with residual disease <1 cm
may improve survival when complete cytoreduction is not feas-
ible and can be an option. Also in the recurrent setting, a signifi-
cantly increased PFS and OS was found after secondary
cytoreductive surgery without residual disease [227]. While car-
boplatin/paclitaxel is still the standard systemic therapy in low-
grade serous ovarian cancer, multiple retrospective studies
showed lower response rates and less survival benefit from
chemotherapy compared with high-grade serous ovarian cancer,
implicating a limited chemosensitivity [228–231]. Similar find-
ings were found in mucinous [45, 232] and clear cell EOCs [233,
234]. Being less chemosensitive, the role of surgery is enhanced
and novel therapeutic strategies for systemic treatment of low-
grade serous ovarian cancer are being investigated (e.g. antihor-
monal and targeted therapies).
The majority of low-grade serous ovarian cancers have high ER
and PR expression. Small retrospective studies suggest a possible
therapeutic value of hormone therapy in first-line and recurrent
settings [42, 235, 236]. Despite promising results with selumeti-
nib, an MEK1/2 inhibitor [237], no correlation was found be-
tween BRAF or KRAS mutation status and therapeutic response
in patients with recurrent low-grade serous ovarian cancer. Of
note, a phase III RCT of an MEK inhibitor versus physician’s
choice of chemotherapy in recurrent platinum-resistant low-
grade serous ovarian cancer was prematurely closed for futility at
the first interim analysis.
Regarding other targeted therapies, bevacizumab has shown
activity in low-grade serous ovarian cancer in first-line and recur-
rent settings in three small retrospective cohorts [238–240].
Hamanishi et al. [241] investigated the effect of nivolumab, an
antibody that blocks programmed cell death protein 1 (PD-1)
signalling, in patients with platinum-resistant ovarian cancer.
One out of the two patients with clear cell histology included in
this trial showed a complete remission with nivolumab. The high
frequency of mismatch repair deficiency in clear cell carcinomas
can provide an explanation for this behaviour towards PD-1
inhibitors. Pembrolizumab, another anti-PD-1 inhibitor, has
been approved by the FDA in solid tumours with microsatellite/
mismatch repair deficiency including ovarian cancer [242].
Further investigation is currently ongoing.
Advanced (FIGO III and IV) non-high-grade serous ovarian
cancer in first line.
Recommendation 15.1: primary debulking surgery with no
macroscopic residual disease is of pivotal importance due the low
chemosensitivity in low-grade serous, mucinous and clear cell
ovarian carcinoma.
Level of evidence: IV
Strength of recommendation: A
Consensus: 100% (38) yes, 0% (0) no, 0% (0) abstain (38 voters)
Recommendation 15.2: even debulking with residual disease
<1 cm in low-grade serous ovarian cancer may improve survival
when complete cytoreduction is not feasible.
Level of evidence: IV
Strength of recommendation: C
Consensus: 100% (38) yes, 0% (0) no, 0% (0) abstain (38 voters)
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Recommendation 15.3: carboplatin in combination with pacli-
taxel is the standard chemotherapy. Addition of bevacizumab
should be considered.
Level of evidence: I
Strength of recommendation: B
Consensus: 97.4% (37) yes, 0% (0) no, 2.6% (1) abstain (38
voters)
Recommendation 15.4: maintenance antioestrogen therapy
after chemotherapy can be considered in low-grade serous ovar-
ian cancer.
Level of evidence: IV
Strength of recommendation: C
Consensus: 92.1% (35) yes, 0% (0) no, 7.9% (3) abstain (38
voters)
Recurrent non-high-grade serous ovarian cancer in first line.
Recommendation 15.5: secondary debulking surgery should be
considered with the aim of no macroscopic residual disease.
Level of evidence: I
Strength of recommendation: B
Consensus: 100% (37) yes, 0% (0) no, 0% (0) abstain (37 voters)
Recommendation 15.6: in low-grade serous, low-grade endo-
metrioid, mucinous and clear cell ovarian carcinoma, chemo-
therapy is an option but the magnitude of benefit is uncertain.
Level of evidence: IV
Strength of recommendation: B
Consensus: 100% (37) yes, 0% (0) no, 0% (0) abstain (37 voters)
Recommendation 15.7: antioestrogen therapy can be consid-
ered in low-grade serous ovarian cancer and low-grade endome-
trioid ovarian carcinoma.
Level of evidence: IV
Strength of recommendation: B
Consensus: 97.3% (36) yes, 0% (0) no, 2.7% (1) abstain (37 voters)
Recurrent disease
16. What is a reasonable monitoring and follow-up strategy fol-
lowing treatment of ovarian cancer?
Currently, evidence is lacking to demonstrate that routine
follow-up of patients treated for ovarian cancer improves out-
come [243–246]. However, monitoring for recurrence might be-
come more important if surgery for recurrent ovarian cancer is
shown to improve survival [247]. There is no evidence support-
ing a different follow-up regimen according to histotype, al-
though it is recognised that not all tumours are associated with
raised levels of CA-125 [248]. At each visit, symptoms should be
assessed and a physical examination should be carried out, al-
though the latter has limited value in detecting relapse. Health-
related QoL (HRQoL) measures, such as EORTC QLQ C30 and
EORTC QLQ OV28, are potentially useful tools to assess symp-
toms [249, 250], and could be adapted to be applied for routine
use. Further to clinical examination and checking for symptoms,
CA-125 is the simplest tool to trigger imaging and is a better ap-
proach than regular routine imaging for diagnosis of recurrent
ovarian cancer [244, 251]. Radiographic imaging, such as ultra-
sound, chest-abdomen-pelvis CT, whole-body MRI or PET-CT,
should only be carried out if clinically indicated, based on
symptoms, clinical examination or a rising CA-125 level [252–
255]. Mucinous and clear cell ovarian cancers could represent a po-
tential source of PET-negative findings [256]. At present, CA-125
remains the most important of the various biomarkers available for
the detection of recurrent ovarian cancer [257], however, an RCT
[258] did not show any survival advantage for initiating chemo-
therapy based on early detection of a higher CA-125 concentration.
It should be noted that this trial was not carried out in an era where
surgery could be considered for selected cases, or where targeted
therapies were used as a maintenance strategy for treatment of re-
current disease to lengthen disease control or survival.
A holistic approach, including patient education about signs
and symptoms, monitoring and management of side-effects,
assessing the psychological and existential consequences of cancer
is needed. Evaluation and support of family and social needs,
counselling for genetic risk, guidance on fertility and contracep-
tion after ovarian cancer, management of menopausal symptoms
and promotion of cardiovascular, bone, brain and sexual health
should all be applied in the follow-up of ovarian cancer patients
[259]. Oestrogen (þ/– progestin) replacement is not contraindi-
cated for severe menopausal symptoms, but the safety of hormo-
nal replacement therapy in low-grade serous and low-grade
endometrioid tumours is unclear [236, 260].
Follow-up is usually offered by gynaecological oncologists or
dedicated medical oncologists. However, there is lack of evi-
dence to show that it needs to be restricted to these groups, and
specialised nurses or general practitioners could also be involved
in the follow-up of ovarian cancer patients [261–263]. Follow-
up should be organised according to a locally agreed protocol.
When follow-up is planned, a reasonable approach involves pa-
tient assessment every 3–4 months for the first 2 years, and every
6 months during years 3–5, but follow-up schemes may be individ-
ualised according to prognostic factors and treatment modalities.
Further follow-up beyond 5 years should be individually discussed
[248, 264]. Monitoring of maintenance therapy should be
specialist-led and focus on the evaluation of toxicity and assess-
ment of disease activity. Local protocols should be established spe-
cifically for the follow-up of patients on maintenance therapy.
Imaging should be carried out according to symptoms and CA-125
levels or periodically if the CA-125 level was normal at the start of
treatment. Follow-up after treatment of recurrent ovarian cancer
should be specialist-led, as further recurrence is inevitable.
Recommendation 16.1: follow-up should be offered, and the
value should be discussed individually with patients, as there is
uncertainty about the benefit of early diagnosis and treatment of
recurrent disease.
Level of evidence: II
Strength of recommendation: C
Consensus: 100% (38) yes, 0% (0) no, 0% (0) abstain (38 voters)
17. What is the place of surgery for recurrent disease?
Cytoreductive surgery.
Results of the Arbeitsgemeinschaft Gynäkologische Onkologie
(AGO) DESKTOP III study [265] demonstrated improved PFS
and a longer time to first subsequent therapy (TFST) in patients
with first recurrence randomised to secondary cytoreductive sur-
gery. The PFS advantage of surgery was only seen following
Annals of Oncology Special article
doi:10.1093/annonc/mdz062 | 689
complete tumour resection and, therefore, complete resection
should be regarded a prerequisite for a potential OS benefit. OS in
DESKTOP III is not yet mature and the results are expected in
2019. Recently shown data of an interim futility analysis of another
trial (GOG 213) [266] failed to demonstrate a PFS or OS advan-
tage. It should be noted that patients in this trial were not systemat-
ically selected and the CRR was lower. Currently, the option of
secondary cytoreductive surgery followed by platinum-based com-
bination therapy should be discussed with all eligible patients
[247]. Patients should be selected if they have a high probability of
having a complete resection and the following predictors for resec-
tion should be considered: platinum treatment-free interval (TFI)
of>6 months, positive AGO score [good PS, complete resection at
primary surgery and the absence of large volume (>500 mL) asci-
tes], absence of probably irresectable lesions on imaging and ab-
sence of contraindications to surgery (e.g. comorbidities, prior
severe complications of surgery) [267]. It is important to note that
platinum TFI and the AGO score have only been developed as
positive predictors of complete resection and cannot be used to ex-
clude patients from surgery. Additionally, centres offering second-
ary cytoreductive surgery should have the necessary resources and
infrastructures including an established multidisciplinary team
coordinating the pre-, intra- and post-operative care needed to
achieve complete resection in the majority of these procedures
[191]. In second or later recurrence there is limited evidence that
highly selected patients (based on PS, tumour biology and localisa-
tion of metastasis) may benefit from complete cytoreductive sur-
gery in specialised centres [268, 269].
Recommendation 17.1: complete cytoreductive surgery fol-
lowed by systemic treatment improves PFS and extends benefit to
the next line of treatment in selected patients with first recurrence
of ovarian cancer; OS data are not yet mature. Patients eligible for
cytoreductive surgery should be informed about this option.
Level of evidence: I
Strength of recommendation: A
Consensus: 100% (38) yes, 0% (0) no, 0% (0) abstain (38 voters)
Recommendation 17.2: complete cytoreductive surgery in se-
cond or later recurrence may provide benefit in selected patients
and specialised centres.
Level of evidence: V
Strength of recommendation: A
Consensus: 100% (37) yes, 0% (0) no, 0% (0) abstain (37 voters)
HIPEC.
Until now, there are no appropriately designed prospective stud-
ies on the effect of HIPEC added to secondary cytoreductive sur-
gery in recurrent ovarian cancer. The results of multiple RCTs on
HIPEC in recurrent ovarian cancer are awaited. Until these
results are available, HIPEC remains an experimental therapy
with potential harm and should only be offered in the context of
well-designed, prospective RCTs. An objective benefit of HIPEC
in relapsed ovarian cancer would need to take account of survival
outcome and acceptability of the side-effects.
Recommendation 17.3: in recurrent ovarian cancer, HIPEC
added to cytoreductive surgery has not been proven to be benefi-
cial in appropriately designed prospective studies.
Level of evidence: IV
Strength of recommendation: A
Consensus: 100% (38) yes, 0% (0) no, 0% (0) abstain (38 voters)
Palliative surgery.
Malignant bowel obstruction (MBO) occurs frequently in patients
with relapsed ovarian cancer. Although MBO is a frequent compli-
cation of ovarian cancer, the treatment given to patients is not
based on high-level evidence. The available evidence on MBO has
been summarised and integrated into a practical treatment algo-
rithm (see Figure 5). In the medical management, corticosteroids
(6–16 mg dexamethasone i.v. daily) may help to resolve MBO,
with few side-effects [270]. Steroids should be tailed off after a few
days if there is no benefit, and be appropriately reduced if there is a
response to treatment. Octreotide can be added and is more effect-
ive than scopolamine butylbromide in controlling symptoms of
MBO [271]. Corticosteroids, octreotide and lanreotide have all
been shown to provide some benefit in symptom control in recur-
rent ovarian cancer and MBO. The role of surgery for MBO
remains unclear. One retrospective study showed a survival advan-
tage following surgery for MBO compared with octreotide [272].
In a Cochrane systematic review [273], the resolution of the symp-
toms of MBO following surgery varied from 26.7% to >68%, and
successful oral feeding was established in 30%–100% of patients.
However, reporting on surgical management of MBO needs stand-
ardisation, as there are a wide variety of possible surgical techni-
ques and indications [274]. Perri et al. [275] suggested a scoring
system to help select patients who were least likely to benefit from
palliative surgery, based on age (>60 years), albumin (<25 g/L)
and ascites (>2 L). In this study [275], patients who were eligible
for bypass/resection and anastomotic procedures had a significant-
ly better prognosis than those receiving a colostomy or ileostomy.
Other surgical alternatives for MBO are percutaneous endoscopic
gastrostomy tube and colorectal stent placement [276, 277].
Further data need to be collected prospectively on morbidity asso-
ciated with both surgical and medical interventions for MBO. The
role of surgery for MBO should be further clarified using objecti-
fied outcome measures, such as the ability to receive enteral feeding
and QoL scores. Furthermore, data concerning re-obstruction
rates, severe surgical complications, pain control, patient satisfac-
tion and survival should also be collected in these studies.
Recommendation 17.4: MBO should be managed on an indi-
vidual basis. There is a lack of evidence for optimal management
and a need for clinical trials to evaluate medical, endoscopic and
surgical approaches.
Level of evidence: V
Strength of recommendation: A
Consensus: 100% (37) yes, 0% (0) no, 0% (0) abstain (37 voters)
18. How should molecularly targeted therapy be integrated into
the management of recurrent ovarian cancer?
Angiogenic therapy.
Bevacizumab is approved in combination with platinum-based
combination therapy and then as maintenance therapy in
patients with a platinum-free interval (PFI) exceeding 6 months,
and with non-platinum single-agent chemotherapy in patients
Special article Annals of Oncology
690 | Colombo et al.
with shorter PFI. The OCEANS trial [25] showed an improve-
ment in PFS in patients treated with bevacizumab [15 mg/kg/
every 3 weeks (q3w)] in combination with carboplatin/gemcita-
bine, who relapsed >6 months since last platinum and had no
previous anti-VEGF treatment. OS was similar in both groups,
which might partially be explained by the use of bevacizumab as a
subsequent anticancer therapy in 43.9% of patients who were
allocated to placebo in the study [278]. The administration of
bevacizumab in combination with paclitaxel/carboplatin in the
GOG 213 study [279] showed a similar improvement in PFS.
Also, the combination of bevacizumab with non-platinum sin-
gle-agent chemotherapy [pegylated liposomal doxorubicin
(PLD), weekly paclitaxel or topotecan] improved PFS in patients
who relapsed<6 months after a first or second line of platinum-
based therapy [23]. In the AURELIA trial [23], very strict inclu-
sion criteria were used to limit the risk for gastrointestinal perfor-
ation. Patients were excluded if they had more than two prior
lines of treatment, a history of bowel obstruction, platinum-
refractory disease or significant serosal disease of the large bowel,
especially if it involved the sigmoid colon. Overall, the addition
of bevacizumab to chemotherapy with either weekly paclitaxel,
PLD or topotecan significantly improved the median PFS. By
using these criteria, only 2.2% of patients receiving bevacizumab
developed a gastrointestinal perforation [23]. The patient-
reported outcomes (PROs) analysis of the study shows that
chemotherapy combined with bevacizumab improved gastro-
intestinal symptoms more often compared with chemotherapy
alone, especially in patients with ascites at the start of treatment
[280]. In both the AURELIA and GOG 2013 trials [29, 214], only
10% of patients or less received prior bevacizumab treatment.
Data presented at the ASCO 2018 Congress showed that,
for patients previously treated with bevacizumab in first line
and relapsing 6 months after last platinum treatment, re-
challenge with bevacizumab in combination with platinum-
based doublets was associated with a significantly prolonged
PFS [281].
Recommendation 18.1: bevacizumab in combination with
platinum-based second-line chemotherapy (gemcitabine or
paclitaxel) followed by bevacizumab maintenance has proven
benefit with respect to tumour response rate and PFS and could
be recommended.
Patients with MBO
Clinical evaluation, medical history, comorbidities, PS and nutritional status, labs
Resuscitative measures (including nasogastric tube, hydration, dietary measures and corticosteroids) and supportive care
Imaging and diagnostic assessment: Abdominal X-ray, CT scan, endoscopy 
Type of bowel obstruction





Multiprofessional and multidisciplinary conference: development of a treatment strategy based on the patient’s wishes and 
resilience, spiritual needs, physical and psychosocial conditions and fi ndings of clinical, laboratory and radiological exams
Palliative surgery
Resection or bypass










Figure 5. Algorithm for the management of MBO.
CT, computed tomography; MBO, malignant bowel obstruction; PS, performance status.
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Level of evidence: I
Strength of recommendation: A
Consensus: 100% (38) yes, 0% (0) no, 0% (0) abstain (38 voters)
Recommendation 18.2: bevacizumab in combination with
second- or third-line non-platinum chemotherapy (weekly pacli-
taxel, PLD, topotecan) has proven benefit with respect to tumour
response rate and PFS, has been associated with improvement in
QoL and could be recommended.
Level of evidence: I
Strength of recommendation: A
Consensus: 100% (38) yes, 0% (0) no, 0% (0) abstain (38 voters)
PARP inhibitors.
Currently, there are three PARP inhibitors approved for the treat-
ment of platinum-sensitive ovarian cancer. Olaparib maintenance
treatment following platinum-based chemotherapy in patients
with a BRCA mutation led to an improvement in PFS in study 19
[35] and in the SOLO2 trial [36]. In study 19, patients without a
BRCA mutation also derived a significant benefit in PFS. There was
no significant OS benefit in study 19. In this study, 11% of patients
remained on treatment for >6 years without evidence of progres-
sion. The OS data for SOLO2 are not yet mature [45, 46]. The
NOVA trial [38] with maintenance niraparib showed improved
median PFS for both germline BRCA-mutated ovarian cancer and
non-germline-mutated BRCA. The latter group included patients
with a somatic BRCA mutation or BRCA WT [38]. In ARIEL3
[37], rucaparib given after a response to platinum-based therapy
showed similar results in patients with BRCA mutations (germline
or somatic mutations) as well as in the whole ITT group with high-
grade cancer. Both NOVA and ARIEL3 trials included tumour test-
ing for HRD, but neither was able to exclude a benefit from PARP
inhibitors in HRD-negative patients. However, the magnitude of
benefit of each of these PARP inhibitors was greatest in patients
with a BRCA mutation, and least in those who were HRD-
negative. Testing for a BRCA mutation is predictive for a response
and provides an opportunity to identify mutations in unaffected
family members who may benefit from cancer prevention strat-
egies. Testing is recommended for all patients with non-mucinous
ovarian cancers. Olaparib maintenance was permitted beyond pro-
gression, and both olaparib and niraparib studies led to an increase
in the time to the next line of treatment, a clinically meaningful
end point [35, 36, 38].
Toxicity of PARP inhibitors is generally manageable through
dose reductions and interruptions of therapy [36–38]. Two studies
[282, 283] have clearly shown a benefit for monotherapy with a
PARP inhibitor in BRCA-mutated, relapsed high-grade ovarian
carcinoma. A combination of two studies with rucaparib, ARIEL2
and study 10, led to the EMA approval of rucaparib in Europe as a
monotherapy for relapsed or progressive BRCA-mutated (germ-
line and/or somatic) HGSC, previously treated with 2 lines of
platinum-based chemotherapy and unsuitable for further treat-
ment with platinum-based chemotherapy [283]. In Europe, the li-
cense for monotherapy is restricted to rucaparib and is only
indicated for in patients with ‘platinum-sensitive’ disease [284].
More recently, the SOLO 3 study randomised 266 patients with
high-grade serous or endometrioid g-BRCA recurrent platinum-
sensitive ovarian cancer to receive olaparib or non-platinum
chemotherapy. Although the data have not been presented as yet, a
public announcement reported statistically significant results in
terms of response rate and PFS in favour of the olaparib arm.
Recommendation 18.3: PARP inhibitors (olaparib, niraparib
and rucaparib) when given as maintenance therapy following a
response to platinum-based second or higher line of treatment
have proven benefit with respect to PFS and could be recom-
mended. The benefit is greatest in, but is not limited to, patients
with a BRCA mutation.
Level of evidence: I
Strength of recommendation: A
Consensus: 100% (34) yes, 0% (0) no, 0% (0) abstain (34 voters)
Recommendation 18.4: PARP inhibitors (rucaparib*, ola-
parib) are active as monotherapy in patients with a BRCA muta-
tion and could be considered.
*In Europe, only rucaparib is licensed by the EMA as a monother-
apy for patients with ‘platinum-sensitive’ disease.
Level of evidence: III
Strength of recommendation: B
Consensus: 100% (38) yes, 0% (0) no, 0% (0) abstain (34 voters)
19. What defines platinum resistance and how does that
influence subsequent treatment?
How should platinum resistance be defined (primary and
secondary resistance)?
Primary platinum resistance is a condition that is intrinsic to the
tumour or occurs during first-line therapy, and leads to progres-
sive disease during or immediately after therapy. Secondary plat-
inum resistance is an acquired condition appearing or emerging
after response to platinum therapy. Use of the terms ‘platinum-
sensitivity’ or ‘-resistance’ varies; most commonly, ‘platinum-re-
sistance’ has been a probabilistic definition, based on a likely poor
response to platinum therapy. Similarly, ‘platinum-sensitivity’
has been defined as a patient likely to respond to platinum ther-
apy. The latter must be separated from true observed platinum
sensitivity in patients who respond to a platinum re-challenge and
may be candidates for further maintenance therapy.
However, it is now questionable whether the historical pro-
spective assumption of platinum sensitivity (or resistance) used
for planning therapy in recurrent disease is valid. The PFI has
been the main indicator to classify tumours as ‘platinum-sensi-
tive’ or ‘-resistant’ based on a 6-month cut-off from the last
platinum-based therapy [285]. This definition, which evolved at
a time when there were few options for treating recurrent disease
other than platinum re-challenge, has several shortcomings and
was abandoned during the Fifth Ovarian Cancer Consensus
Conference (OCCC) of the GCIG [285]. For example, increasing-
ly the majority of patients undergo a complete resection of their
advanced ovarian cancer during primary surgery, making a re-
sponse evaluation afterwards impossible. Growth rate and tu-
mour kinetics may differ among different histological types, and
a 6-month cut-off cannot reliably separate those who responded
or did not respond in this subgroup. Furthermore, not all
patients having experienced a TFI from platinum (TFIp) longer
than 6 months later respond to platinum and objective response
rates range from 47.2% to 66% [25, 279, 286, 287]. In addition,
TFIp shorter than 6 months is not always predictive of absence of
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response to platinum-based therapy. The interval may also de-
pend on the frequency of follow-up and the sensitivity of diagnos-
tic tools applied in a particular patient. Both weekly paclitaxel/
carboplatin and carboplatin/gemcitabine displayed clinical effi-
ciency in ‘platinum-resistant’ disease, with an overall response rate
of 29% with both regimens [288, 289]. BRCA-mutated patients in
particular, but also BRCA WT patients, may respond to re-
challenge with platinum-based chemotherapy, even with a TFIp of
<6 months [47]. For both groups, the response rate to platinum-
based chemotherapy upon relapse within 6 months after first-line
treatment was higher compared with non-platinum regimens [47].
Furthermore, the benefit of new biological drugs may not necessar-
ily follow this historical paradigm; for example, PARP inhibitors
are active in both cohorts of patients [290].
How can we predict platinum resistance?
Currently, there are no validated, molecular, predictive biomarkers
for platinum resistance. Several genetic modifications are associated
with acquired resistance to platinum-based chemotherapy, such as
inactivation of the tumour suppressors RB1, NF1, RAD51B and
PTEN, reversions of germline or somatic BRCA1 or BRCA2 muta-
tions, overexpression of the drug efflux pump MDR1 and CCNE1
amplification [51]. The probability of platinum response also
depends on the histological subtype, and, in the case of low-grade
serous, clear cell or mucinous ovarian carcinomas, the response to
platinum-based therapy is known to be poor. Low baseline global
health status, poor physical function and the presence of abdominal/
gastrointestinal symptoms are predictors of early discontinuation
(within the first 8 weeks of treatment) of chemotherapy among
patients with early relapse or after three lines of chemotherapy [291].
Patients with a poor PS should be informed about the low probabil-
ity of response to further platinum or non-platinum chemotherapy.
However, all patients with recurrent ovarian cancer should be offered
early palliative care, even though there are currently no data showing
benefit specifically for ovarian cancer. A meta-analysis [292] of rand-
omised studies in advanced cancers (that cannot be cured) indicates
that early palliative care may significantly improve QoL, decrease the
intensity of symptoms and possibly improve survival.
The definition of platinum resistance should be therapy-oriented.
As TFI decreases, prognosis following subsequent treatment wor-
sens; when the interval is <6 months, the anticipated median OS
is around 10–12 months. At this point, the objective of treatment
should be to control symptoms with a minimum of side-effects,
thereby preserving QoL. Response rates to platinum or non-
platinum monotherapy regimens are all relatively similar. For
patients for whom platinum-based therapy is no longer an option,
sequential non-platinum therapy regimens can be offered. This
group should be defined as those patients who have progressed
while receiving platinum-based chemotherapy or experienced a
symptomatic relapse soon after the end of the last platinum-based
chemotherapy, and those for whom there is a contraindication to
use further platinum-based treatment, such as allergy [293]. Non-
platinum drugs should be selected based on the toxicity profile
and patient preference. The addition of bevacizumab to non-
platinum regimens such as PLD, weekly paclitaxel or topotecan
improves PFS and has also shown a reduction in ascites and im-
provement in gastrointestinal symptoms [23, 24, 280].
Patients should be considered for further platinum therapy
when platinum is not contraindicated or they do not have defin-
ite resistance, as described above. Tumour response rates to
platinum are at least as good as to non-platinum drugs in this set-
ting. Following a response, patients should be considered for
maintenance treatment with a PARP inhibitor (see Figure 6).
Additionally, platinum re-challenge could be considered follow-
ing treatment with a non-platinum regimen (monotherapy or
combination) if the criteria in Figure 6 suggesting that platinum
‘might not be the best option’ do not apply.
Treating patients with relapsed ovarian cancer.
First, it should be determined if a patient is fit for anticancer ther-
apy and willing to receive further treatment (see Figure 6). Next,
the question of surgery should be considered (particularly for
patients in first relapse) possibly by using the AGO scoring sys-
tem. Tumour biology, histology, prior therapies, prior response
to chemotherapy, TFIp (which continues to have prognostic
value), persistent toxicity, patient preference and current symp-
toms all need to be taken into account when making a decision
about whether or not to offer platinum-based therapy or non-
platinum treatment. Patients for whom platinum-based chemo-
therapy might not be the best option are a heterogeneous group,
containing both patients with early symptomatic relapse or pro-
gression during prior platinum-based chemotherapy and patients
with platinum intolerability. These patients should be offered a
non-platinum regimen, possibly in combination with bevacizu-
mab. Patients who are potentially platinum-responsive should
receive platinum re-challenge. In highly symptomatic patients
who have no contraindications for bevacizumab the combination
of platinum-based therapy with bevacizumab could be consid-
ered. Bevacizumab with platinum combinations (either paclitaxel
or gemcitabine followed by bevacizumab maintenance) has dem-
onstrated a significant benefit in PFS [25, 266, 278, 279].
Recently, PLD in combination with platinum and bevacizumab
has been compared with carboplatin/gemcitabine and bevacizu-
mab (ENGOT-ov18/AGO-OVAR 2.21 [294]) and showed a sig-
nificant PFS advantage compared with carboplatin/gemcitabine
combined with bevacizumab. In patients with a BRCA mutation
in this setting, there are no data comparing monotherapy with
rucaparib to chemotherapy with bevacizumab, but the higher re-
sponse rate seen when adding bevacizumab to chemotherapy
would favour this combination. For asymptomatic patients with
a BRCA mutation and PFI >6 months, either rucaparib mono-
therapy or platinum-based chemotherapy followed by a PARP in-
hibitor could be considered. Patients who have no priority for
urgent symptomatic response, or in whom bevacizumab is con-
traindicated, such as thrombosis, fistula, etc., should be offered a
PARP inhibitors if they respond to platinum re-challenge, irre-
spective of their BRCA mutation status. For relapsed ovarian can-
cer, licensed drugs in Europe include paclitaxel, PLD, topotecan
and the combination of trabectedin and PLD in patients with
platinum-sensitive disease. This combination has shown superior
efficacy compared with PLD monotherapy and can be considered
in patients unable to tolerate further platinum, having relapsed
>6 months after platinum.
Recommendation 19.1: there are currently no molecular
biomarkers to predict platinum response.
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• Resistance to platinum in recurrent ovarian cancer is a
therapy-oriented definition:
8 Proven platinum resistance: progression during platinum
therapy
8 Assumed/expected platinum resistance: early symptomatic
relapse with low probability of response to platinum; these
patients should be treated with sequential non-platinum
therapy adding bevacizumab if indicated.
• Sensitivity to platinum in recurrent ovarian cancer is a
therapy-oriented definition:
8 Proven platinum sensitivity: response to platinum; these
patients can receive maintenance PARP inhibitors
8 Assumed/expected platinum sensitivity: previous response
to platinum without early symptomatic relapse; these
patients should be treated with platinum-based therapy
adding bevacizumab or followed by maintenance PARP
inhibitor therapy, if indicated. This group includes those
who did not receive prior platinum or those who received
adjuvant platinum post-surgery without any evaluable re-
sidual disease to assess chemotherapy response.
Level of evidence: I–IV
Strength of recommendation: A
Consensus: 85.7% (30) yes, 11.4% (4) no, 2.9% (1) abstain (35
voters)
Recommendation 19.2: platinum re-challenge following treat-
ment with a non-platinum regimen (monotherapy or combin-
ation) could be considered if a patient had not progressed during
prior platinum therapy.
Level of evidence: IV
Strength of recommendation: A
Consensus: 100% (34) yes, 0% (0) no, 0% (0) abstain (34 voters)
Recommendation 19.3: early palliative care should be inte-
grated into the management of patients with recurrent ovarian
cancer.
Level of evidence: V
Strength of recommendation: A
Consensus: 100% (34) yes, 0% (0) no, 0% (0) abstain (34 voters)
Recommendation 19.4: incorporating HRQoL tools in the care
of patients with a low probability of response to platinum may
identify patients for whom subsequent therapy is futile, and this
information should be discussed with the patient.
Level of evidence: III
Strength of recommendation: A
Consensus: 100% (34) yes, 0% (0) no, 0% (0) abstain (34 voters)
20. How long should therapy be continued in recurrent disease?
There are no RCTs studying the recommended length of treat-
ment in recurrent ovarian cancer. In the CALYPSO trial [295]
Patients with recurrent ovarian cancer
Tumour biology/histology










Platinum might be the best option/rechallenge appears justifi ed
Response to prior platinum-based chemotherapy
Best supportive care
Platinum might not be the best option
Early symptomatic relapse
Progression on prior platinum-based chemotherapy
Platinum intolerability
Non-eligible for platinum/potentially platinum 
non-responsive or platinum-contraindicated
Non-platinum therapy
No priority for symptomatic 
response or contraindications 
to bevacizumab 
Priority for symptomatic 
response and no contraindications 
to bevacizumab
Eligible for platinum/potentially platinum-responsive
If indicated: plus bevacizumab
Platinum-based rechallenge Offer platinum-based rechallenge 
plus bevacizumab
Offer PARP inhibitors after response 
to platinum if not contraindicated 
(observed platinum response)
Figure 6. Algorithm for the treatment of patients with recurrent ovarian cancer.
AGO, Arbeitsgemeinschaft Gynäkologische Onkologie; PARP, poly(adenosine diphosphate-ribose) polymerase; TFI, treatment-free interval.
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and the AGO 2.5 study protocol [286], most patients received 6
cycles of carboplatin in combination with PLD/paclitaxel/gemci-
tabine. However, in CALYPSO [295], 10% of patients received
9 cycles of chemotherapy instead of 6. Similarly, in the AGO-
OVAR 2.5 study [286], in which administration of 9–10 cycles of
carboplatin/gemcitabine was allowed at the physician’s discre-
tion, a limited number of patients received>6 cycles. The ICON4
study protocol [287] stated that at least 6 cycles of carboplatin/
paclitaxel should be given but the exact number of cycles was not
published. In non-platinum-based studies protocols usually state
that treatment can be given to progression (or toxicity).
Frequently, the number of cycles is <6. For example, in a study
[296] comparing PLD and topotecan, platinum-resistant patients
received on average 4.9 cycles of PLD and 5.7 cycles of topotecan.
However, without evidence to the contrary, non-platinum treat-
ment is often given until progression or toxicity occurs.
Stopping chemotherapy.
Recommendation 20.1: for platinum-based chemotherapy,
6 cycles are recommended. More or fewer cycles have not been
shown to be beneficial, and consideration should be given to the
toxicity.
Level of evidence: V
Strength of recommendation: B
Consensus: 100% (34) yes, 0% (0) no, 0% (0) abstain (34 voters)
Recommendation 20.2: for non-platinum chemotherapies,
treatment may be continued as long as there is clinical benefit
and treatment is well-tolerated.
Level of evidence: V
Strength of recommendation: B
Consensus: 100% (34) yes, 0% (0) no, 0% (0) abstain (34 voters)
In the OCEANS and GOG 213 trials [278, 279], maintenance
therapy with bevacizumab treatment was stopped upon disease
progression. In the AURELIA trial [23], bevacizumab was not
offered as a maintenance therapy; chemotherapy in combination
with bevacizumab was continued to progression. Based on these
results, it remains unclear when to stop bevacizumab treatment.
Caution should be exercised in stopping treatment too early on
the basis of a slow rise in CA-125, either alone or with minor CT
abnormalities. It is difficult to state that a patient at this point will
no longer benefit from continuing bevacizumab. Consideration
should be given to continuing bevacizumab until symptomatic
progression or the next line of treatment is started.
Stopping bevacizumab.
Recommendation 20.3: recommended length of treatment
remains unclear. Treatment is usually continued until disease
progression. The continuation of bevacizumab beyond progres-
sion has not been evaluated in the recurrent setting.
Level of evidence: V
Strength of recommendation: B
Consensus: 97.1% (33) yes, 2.9% (1) no, 0% (0) abstain (34 voters)
Both in study 19 and SOLO2, progression was determined by
Response Evaluation Criteria In Solid Tumours (RECIST) v1.1
criteria, but patients could continue olaparib beyond progression
[34, 36]. For these patients the TFST could provide insight into
the effect of treating beyond progression. For SOLO2 [36], TFST
analysis was preplanned and showed an additional advantage of
7.2 months, comparing the difference between the median TFST
and PFS for patients who received olaparib compared with pla-
cebo. In the NOVA and ARIEL3 trials [43, 44], PARP inhibitor
treatment was discontinued upon progression. Currently, the
recommended length of PARP inhibitor treatment, based on
these results, remains unclear. However, treatment beyond pro-
gression, until the next line of chemotherapy should be consid-
ered, and may have clinical value.
Stopping maintenance PARP inhibitors.
Recommendation 20.4: recommended length of treatment
remains unclear. Despite an increase in TFST demonstrated for
olaparib and niraparib, the benefit of continuing treatment be-
yond progression has not been demonstrated conclusively to date.
Level of evidence: III
Strength of recommendation: A
Consensus: 100% (34) yes, 0% (0) no, 0% (0) abstain (34 voters)
In gynaecological oncology practice, there is consensus on the
importance of PROs (QoL and symptoms) and the incorporation
of PRO end points in advanced or relapsed disease [250, 297–
300]. The Standard Protocol Items: Recommendations for
Interventional Trials patient-reported outcome (SPIRIT-PRO)
guidelines could be used for preplanned PROs hypothesis [301].
Currently, there are several QoL questionnaires available, such as
the functional assessment of cancer therapy (FACT) Ovarian
Symptom Index, the European Organisation for Research and
Treatment of Cancer (EORTC) QLQ-OV28 and Measure of
Ovarian Symptoms and Treatment (MOST); however, there is no
gold standard available among the QoL questionnaires [302].
Toxicity reported by the patients using the Patient-Reported
Outcomes version of the Common Terminology Criteria for
Adverse Events (PRO-CTCAETM) is a valuable measurement and
could improve the reporting of side-effects and toxicity in the fu-
ture. However, reporting of toxicity by the physicians should also
be adapted to evaluate the clinical relevance by including fre-
quency, timing and duration, in addition to severity and inci-
dence rates [303, 304]. Utility questionnaires such as EQ-5D and
QTwist are developed to calculate QoL-adjusted PFS; they could
add complementary information.
Velikova et al. [305] demonstrated that implementation of
routine evaluation of HRQoL is feasible, increases awareness of
physicians for the importance of QoL and can have a positive im-
pact on the well-being of patients. Recently, Basch et al. [304]
showed that self-evaluation of symptoms could significantly im-
prove QoL during treatment, decrease emergency admissions
and even improve survival of patients with advanced cancers.
The possible negative impact of treatment on QoL due to AEs
should be considered and balanced against the possible positive
effects of treatment to reduce or delay cancer symptoms. Regular
PRO measurement can help to evaluate the benefit a patient has
and can expect from the treatment, and can follow the side-
effects of the treatments (in order to help the physician make
adjustments to therapy).
Recommendation 20.5: PROs and HRQoL should be inte-
grated into the decision-making and the evaluation of treatment
efficacy in all patients with recurrent ovarian cancer.
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Level of evidence: V
Strength of recommendation: A
Consensus: 100% (34) yes, 0% (0) no, 0% (0) abstain (34 voters)
Recommendation 20.6: follow-up of QoL and symptoms
should be integrated into routine practice.
Level of evidence: V
Strength of recommendation: A
Consensus: 100% (34) yes, 0% (0) no, 0% (0) abstain (34 voters)
Psycho-oncological support
Ovarian cancer is a life-threatening condition and its treatment
may produce significant toxicities, which cause substantial short-
and long-term side-effects and functional loss in various behav-
ioural and life domains, as well as psychosocial distress.
Therefore, QoL and functional status of the patient may be sub-
stantially reduced. In coping and adjusting to life with cancer,
women and their families face multiple challenges.
Early detection of psychosocial distress, sexual dysfunction and
psychiatric comorbidity, as well as identification of psychosocial
care needs, are of major importance. A stepped care model of
interventions including counselling, psychoeducation and psy-
chotherapy seems to be the best approach in all areas of psycho-
social care for patients with ovarian cancer. To empower patients
to cope with physical and psychosocial long-term side-effects of
disease and therapy and to preserve QoL they should receive a
personalised survivorship care plan (see Section 2 of supplemen-
tary data, available at Annals of Oncology online).
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